

# Presenting Company Profile Guide

The 17<sup>th</sup> Annual

**BIOTECH SHOWCASE™**

**TECHBIO SHOWCASE**

**SEED SHOWCASE**

Find all the details about the  
Presenting Companies at Biotech  
Showcase, TechBio Showcase and  
Seed Showcase in this guide.

January 13-15, 2025

Co-produced by



# **DEMYCOLTON**

Where Global Biotech Leaders Connect

 **virtualsalons**

Year-round

 **executiveclinics**  
FOR BIOTECH & LIFE SCIENCE LEADERS

Coming  
Spring 2025

 **BIOTECH  
ceosummit**  
USA

July 16-18, 2025  
Napa, CA

 **biofuture™**

October 2025  
New York City, NY

**BIOTECH  
SHOWCASE™**

Including Specialized Showcases

**TECHBIO  
SHOWCASE**

**SEED  
SHOWCASE**

January 12-14, 2026  
San Francisco, CA

[demy-colton.com](http://demy-colton.com)



## Table of Contents

### **BIOTECH SHOWCASE™**

Profiles .....7

Categorical Listings ..... 68

### **TECHBIO SHOWCASE**

Profiles .....82

Categorical Listings .....93

### **SEED SHOWCASE**

Profiles .....98

Categorical Listings ..... 120





2025

# BIOTECH SHOWCASE™

Presenting Company  
Profiles



## **4B Technologies, Ltd**

**Categorical Listings:** CNS/Neurological, Neurology, Neuropathy/Pain

**Location:** Kowloon,  
Hong Kong China

**Established:** 2018

**Website:** 4btechnologies.com

**Presenter:** Sean Zeng, PhD, MBA,  
Global Head, Business Development

**Corporate Partners:** While 4B Technologies currently operates independently, the company is actively exploring strategic partnerships to accelerate its drug development programs and expand its therapeutic capabilities.

**Funds Raised:** INP

---

## **Abacus Bioscience Inc**

**Categorical Listings:** Autoimmune, Immuno-oncology, Inflammation

**Location:** Seattle,  
Washington United States

**Established:** 2023

**Website:** abacusbioscience.com

**Presenter:** Alan Wahl, PhD, MS, CEO

**Corporate Partners:** None yet.

**Funds Raised:** \$5.5M Seed and commenced operations in 2023. Seeking subsequent raise/partnering to bring lead molecule into clinical development.

---

## **Accropeutics**

**Categorical Listings:** Autoimmune, Gastrointestinal, Immunology

**Location:** New York,  
New York United States

**Established:** 2017

**Website:** accropeutics.com

**Presenter:** Kenneth Gao, SVP,  
Corporate Development & Strategy

**Corporate Partners:** Open to partnerships.

**Funds Raised:** \$45M

## **AdAlta Limited** (ASX:1AD)

**Categorical Listings:** Cell Therapy, Fibrosis, Orphan/Rare Disease

**Location:** La Trobe University,  
Australia

**Established:** 2007

**Website:** [adalta.com.au](http://adalta.com.au)

**Presenter:** Tim Oldham, PhD,  
CEO & Managing Director

**Corporate Partners:** Discovery collaborations with Carina Biotech (Australia), GE Healthcare (UK), GPCR Therapeutics (Korea); multiple licensing term sheets in play in China, Korea, Japan, Singapore.

**Funds Raised:** \$30M, leveraged with ~\$10M of grants and R&D Tax Incentive rebates.

---

## **Aegle Therapeutics Corporation**

**Categorical Listings:** Immunology, Inflammation, Orphan/Rare Disease

**Location:** Woburn,  
Massachusetts United States

**Established:** 2019

**Website:** [aegletherapeutics.com](http://aegletherapeutics.com)

**Presenter:** Shelley Hartman, CEO

**Corporate Partners:** None

**Funds Raised:** INP

---

## **Aelis Farma** (Euronext:AELIS)

**Categorical Listings:** CNS/Neurological, Dermatology, Endocrine/Metabolic

**Location:** Bordeaux,  
France

**Established:** 2013

**Website:** [aelisfarma.com](http://aelisfarma.com)

**Presenter:** Pier Vincenzo Piazza,  
MD, PhD, CEO

**Corporate Partners:** AEF0117 is partnered with Indivior.

**Funds Raised:** INP



## **Affinia Therapeutics**

**Categorical Listings:** Cardiovascular, CNS/Neurological, Gene Therapy

**Location:** Waltham,  
Massachusetts United States

**Corporate Partners:** Vertex

**Established:** 2019

**Funds Raised:** \$178M from Series A in 2020 and Series B in 2021.

**Website:** affiniatx.com

**Presenter:** Rick Modi, MBA, CEO

---

## **AIVITA Biomedical, Inc.**

**Categorical Listings:** Immuno-oncology, Personalized Medicine, Vaccines

**Location:** Irvine,  
California United States

**Corporate Partners:** The Company's cancer trials are being conducted in collaboration with hospitals and cancer centers nationwide.

**Established:** 2016

**Funds Raised:** INP

**Website:** aivitabiomedical.com

**Presenter:** Hans Keirstead,  
PhD, Chairman & CEO

---

## **Akadeum Life Sciences, Inc.**

**Categorical Listings:** Cell Therapy, Gene Therapy, Immuno-oncology

**Location:** Ann Arbor,  
Michigan United States

**Corporate Partners:** Akadeum collaborates with top corporations and pioneering leaders in cell therapy, supporting transformative advances in cellular manufacturing and therapeutic applications.

**Established:** 2010

**Funds Raised:** INP

**Website:** akadeum.com

**Presenter:** Brandon McNaughton,  
PhD, CEO

## Alphyn Biologics

**Categorical Listings:** Dermatology, Immunology, Microbiome

**Location:** Annapolis,  
Maryland United States

**Corporate Partners:** None

**Established:** 2020

**Funds Raised:** \$16M

**Website:** [alphynbiologics.com](http://alphynbiologics.com)

**Presenter:** Neal Koller, CEO

---

## Alpina Biotechnology, Inc.

**Categorical Listings:** Autoimmune, Immunology, Inflammation

**Location:** Bedford,  
Massachusetts United States

**Corporate Partners:** None

**Established:** 2022

**Funds Raised:** \$5M

**Website:** INP

**Presenter:** Sena Biswas,  
President & CEO

---

## Alveolus Bio

**Categorical Listings:** Drug Discovery, Inflammation, Pulmonary

**Location:** Cambridge,  
Massachusetts United States

**Corporate Partners:** The company has spoken to several big  
pharma that have requested clinic data.

**Established:** 2021

**Funds Raised:** \$5.5M to date under company.

**Website:** [alveolusbio.com](http://alveolusbio.com)

**Presenter:** Gaurav Mehta, MBA, CEO

---

## **Alyea Therapeutics (Subsidiary of Alt 5 Sigma) (NASDAQ:ALTS)**

**Categorical Listings:** CNS/Neurological, Musculoskeletal, Neuropathy/Pain

**Location:** Las Vegas,  
Nevada United States

**Established:** 2024

**Website:** [sointherapeutics.com](http://sointherapeutics.com)

**Presenter:** Amol Soin, MD, CEO

**Corporate Partners:** All drugs and platforms were developed in house by members of the team and the company maintains all ownership rights.

**Funds Raised:** Alyea Therapeutics (ALTS) is a publicly traded company that has raised several million dollars over the years for its programs.

## **Ananda Immunotherapies SG Pte Ltd**

**Categorical Listings:** Autoimmune, Immunology

**Location:** Singapore

**Established:** 2021

**Website:** [ai-therapies.com](http://ai-therapies.com)

**Presenter:** Adrian Lim, MBA, CEO

**Corporate Partners:** JLABS Singapore member

**Funds Raised:** INP

## **Angiex, Inc.**

**Categorical Listings:** Drug Discovery, Oncology, Platform Technology

**Location:** Cambridge,  
Massachusetts United States

**Established:** 2015

**Website:** [angiex.com](http://angiex.com)

**Presenter:** Paul Jaminet, PhD, CEO

**Corporate Partners:** INP

**Funds Raised:** \$68M

## Aqilion AB

**Categorical Listings:** Autoimmune, Gastrointestinal, Inflammation

**Location:** Helsingborg,  
Sweden

**Established:** 2018

**Website:** aqilion.com

**Presenter:** Sarah Fredriksson,  
PhD, MSc, CEO

**Corporate Partners:** Aqilion has a track record of both in- and out-licensing deal making within the current pipeline.

**Funds Raised:** €25M in two separate rounds - 2018 and 2022 - with the same investor group in both rounds.

## Artery Therapeutics, Inc.

**Categorical Listings:** CNS/Neurological, Longevity/Healthspan/Diseases of Aging, Neuropathy/Pain

**Location:** San Ramon,  
California United States

**Established:** 2004

**Website:** arterytx.com

**Presenter:** Jan Johansson,  
MD, PhD, CEO & Founder

**Corporate Partners:** CS6253 lead molecule in Phase 1-2 is not partnered.

**Funds Raised:** ATI has received NIH-NIA fast-track small business grants and Alzheimer's Association Part the Cloud for CS6253 clinical development.

## AstriVax

**Categorical Listings:** Infectious Disease, Platform Technology, Vaccines

**Location:** Leuven,  
Belgium

**Established:** 2022

**Website:** astrivax.com

**Presenter:** Hanne Callewaert,  
PhD, CEO

**Corporate Partners:** INP

**Funds Raised:** AstriVax was founded in 2022 with €30M Seed money and has additionally raised €6M in non-dilutive funding.

## Atom Bioworks

**Categorical Listings:** Artificial Intelligence (AI), Cell Therapy, Drug Delivery

**Location:** Cary,  
North Carolina United States

**Corporate Partners:** INP

**Established:** 2021

**Funds Raised:** \$3M in 2021.

**Website:** atombioworks.com

**Presenter:** Sherwood Yao,  
MBA, MS, CEO

## AUM Biosciences

**Categorical Listings:** Endocrine/Metabolic, Oncology, Oncology Combination Therapy

**Location:** Singapore

**Corporate Partners:** Lead candidate has a clinical collaboration with Merck (MSD) & Roche. Became a JnJ JLABS company. Licensing deal with Newsora Biopharma.

**Established:** 2018

**Website:** aumbiosciences.com

**Presenter:** Vishal Doshi, MSPS, CEO

**Funds Raised:** \$38M to date including \$27M Series A led by Everstone Capital (\$6B AUM) and multiple strategic investors.

## Aurigene Oncology Limited

**Categorical Listings:** Oncology

**Location:** Bangalore,  
India

**Corporate Partners:** One of the company's oncology programs is being developed by Curis Inc. (Phase III) and the other one by Olema Oncology (Phase II).

**Established:** 2002

**Website:** aurigene.com

**Presenter:** Murali Ramachandra,  
PhD, CEO

**Funds Raised:** \$10M private equity (2002-2005), \$120M via collaborations and milestones (2015-2024) \$78M private equity in 2024.

## **Avistone Biotechnology**

**Categorical Listings:** Oncology

**Location:** Beijing,  
China

**Established:** 2012

**Website:** en.avistonebio.com

**Presenter:** David Chung,  
MBA, MHS, CBO

**Corporate Partners:** Open to discussing global partnering opportunities.

**Funds Raised:** Over \$340M in financing from leading venture firms (Series A and B).

---

## **Avobis Bio**

**Categorical Listings:** Cell Therapy, Gastrointestinal, Regenerative Medicine

**Location:** Newark,  
Delaware United States

**Established:** 2019

**Website:** avobisbio.com

**Presenter:** Tiffany Brown, PhD, CEO

**Corporate Partners:** Company formed by Mayo Clinic and W.L. Gore & Associates.

**Funds Raised:** INP

---

## **Axcynsis Therapeutics**

**Categorical Listings:** Antibodies, Oncology, Platform Technology

**Location:** Singapore

**Established:** 2022

**Website:** axcynsis.com

**Presenter:** Zou Bin,  
PhD, CEO & Founder

**Corporate Partners:** INP

**Funds Raised:** \$15M in Seed Round in 2022. \$6M in Pre-A Round in 2024.

**Azitra Inc.** (NYSE:AZTR)

**Categorical Listings:** Dermatology, Microbiome, Orphan/Rare Disease

**Location:** Branford,  
Connecticut United States

**Established:** 2014

**Website:** azitrainc.com

**Presenter:** Travis Whitfill,  
MPH, MPhil, COO

**Corporate Partners:** Azitra currently has a partnership with Bayer for the development of consumer health products.

**Funds Raised:** Over \$52M in equity to date, plus ~\$3M in grants.

**Bectas Therapeutics Inc.**

**Categorical Listings:** Antibodies, Immunology, Oncology

**Location:** Houston,  
Texas United States

**Established:** 2022

**Website:** bectastx.com

**Presenter:** Ronan O'Hagan,  
President & CEO

**Corporate Partners:** No corporate partners to date.

**Funds Raised:** INP

**Beech Biotech SA**

**Categorical Listings:** Antibodies, Women's Health

**Location:** Lausanne,  
Switzerland

**Established:** 2022

**Website:** beech-biotech.com

**Presenter:** Ian Cottingham, CEO

**Corporate Partners:** None

**Funds Raised:** Privately held

## **Beijing CorreGene Biotechnology Co., Ltd**

**Categorical Listings:** Antibodies, Cell Therapy, Oncology

**Location:** Beijing,  
China

**Corporate Partners:** The company does not have any corporate partners so far.

**Established:** 2016

**Website:** en.corregene.com

**Funds Raised:** In 2019, \$3.08M; 2021, \$12.31M; 2022, \$12.31M; 2024, \$23.08M.

**Presenter:** Xingwang Xie, MD, CEO

---

## **Bexion Pharmaceuticals, Inc.**

**Categorical Listings:** CNS/Neurological, Neuropathy/Pain, Oncology

**Location:** Covington,  
Kentucky United States

**Corporate Partners:** Bexion is seeking corporate partners.

**Established:** 2006

**Funds Raised:** Over \$94M in private funds with an additional \$6.1M in grants from the National Cancer Institute.

**Website:** bexionpharma.com

**Presenter:** Jim Beach, PhD,  
Co-Founder, President & CEO

---

## **Biomia**

**Categorical Listings:** Drug Discovery, Neuropathy/Pain, Psychiatric

**Location:** Copenhagen,  
Denmark

**Corporate Partners:** genOway (FRA) and Univ. Helsinki (FIN) for generating humanised genetic animal models as well as behavioural battery testing.

**Established:** 2022

**Funds Raised:** \$3M pre-Seed in Sept. 2023. \$0.8M in EU grant in 2024.

**Website:** biomia.com

**Presenter:** Michael Krogh Jensen,  
MSc, Co-Founder & CEO



## **Biomissile Pharmaceuticals**

**Categorical Listings:** Antibodies, Autoimmune, Immuno-oncology

**Location:** Shanghai,  
China

**Corporate Partners:** INP

**Established:** 2020

**Funds Raised:** Total \$55M: \$25M Series A in 2020; \$30M Series B in 2023.

**Website:** biomissile.com

**Presenter:** Chao Tu,  
Co-Founder, President & CEO

---

## **BioNova Pharmaceuticals Ltd.**

**Categorical Listings:** Hematology, Oncology, Oncology Combination Therapy

**Location:** Shanghai,  
China

**Corporate Partners:** Former partners included Kadmon Inc, which was acquired by Sanofi for \$1.9B. Sanofi acquired the China right from BioNova for BN101, which BioNova developed and got it approved in China.

**Established:** 2018

**Website:** bionovapharma.com

**Funds Raised:** Series A completed in 2018 with \$17M. Series B completed in 2020 with \$60M.

**Presenter:** Bryan Huang, PhD,  
MBA, CFO & Chief Strategy Officer

---

## **BioStem Technologies, Inc. (OTCMKTS:BSEM)**

**Categorical Listings:** Contract Manufacturing, Regenerative Medicine

**Location:** Pompano Beach,  
Florida United States

**Corporate Partners:** Venture Medical

**Established:** 2014

**Funds Raised:** INP

**Website:** biostemtechnologies.com

**Presenter:** Jason Matuszewski, CEO

## **BioStrategies LC**

**Categorical Listings:** CNS/Neurological, Orphan/Rare Disease, Platform Technology

**Location:** Jonesboro,  
Arkansas United States

**Corporate Partners:** None

**Established:** 2007

**Funds Raised:** \$1.5M of non-dilutive (grant) funding.

**Website:** [biostrategies-lc.com](http://biostrategies-lc.com)

**Presenter:** Carole Cramer, PhD,  
President & Co-Founder

---

## **CELLeBRAIN**

**Categorical Listings:** CNS/Neurological, Gene Therapy, Oncology

**Location:** Suwon,  
South Korea

**Corporate Partners:** The company's MSC-based gene therapy for oncology has been developed in partnership with Hanmi Pharmaceutical and Encell Technology.

**Established:** 2018

**Funds Raised:** \$3.8M in grants till 2025; \$9M to date.

**Website:** [cellebrain.com](http://cellebrain.com)

**Presenter:** Haeyoung Suh-Kim,  
PhD, CEO

---

## **Collectar Biosciences Inc. (NASDAQ:CLRB)**

**Categorical Listings:** Oncology, Oncology Combination Therapy, Radiopharmaceuticals

**Location:** Florham Park,  
New Jersey United States

**Corporate Partners:** INP

**Established:** 2003

**Funds Raised:** More than \$100M with \$25M in 2024.

**Website:** [collectar.com](http://collectar.com)

**Presenter:** Jim Caruso, CEO

## **Cellergy Pharma Inc.**

**Categorical Listings:** Antibodies, Cell Therapy, Immuno-oncology

**Location:** Wilmington,  
Delaware United States

**Corporate Partners:** INP

**Established:** 2021

**Funds Raised:** \$1M

**Website:** cellergypharma.com

**Presenter:** Ronald Dudek,  
MBA, President

---

## **Cellevate AB**

**Categorical Listings:** Biomanufacturing, Gene Therapy, Vaccines

**Location:** Lund,  
Sweden

**Corporate Partners:** Nanofiber products are optimized/  
validated in collaboration with Charles River Laboratories  
(USA), University College of London (UK), BTEC (USA),  
IntraVacc (NL), Sirion Biotech (DE), Max Plank (DE),  
Everzom (FR).

**Established:** 2014

**Website:** cellevate.com

**Presenter:** Laura Chirica, PhD, CEO

**Funds Raised:** Total €12.1M of which €3.2M soft funding.

---

## **CelluGenix Biotech Inc.**

**Categorical Listings:** Cell Therapy, Gene Therapy, Platform Technology

**Location:** Los Angeles,  
California United States

**Corporate Partners:** Various tier I hospitals in China.

**Established:** 2024

**Funds Raised:** \$65M in total.

**Website:** cellugenix.net

**Presenter:** Yuchun Gu,  
MD, PhD, Founder & CEO

**Cereno Scientific AB** (OMX:CRNO-B)**Categorical Listings:** Cardiovascular, Epigenetics, Orphan/Rare Disease**Location:** Mölndal,  
Sweden**Established:** 2012**Website:** [cerenoscientific.com](http://cerenoscientific.com)**Presenter:** Sten R. Sörensen, CEO**Corporate Partners:** A collaboration agreement with global healthcare company Abbott allowed Cereno Scientific to use the cutting-edge technology CardioMEMS HF System in the Phase IIa trial of CS1 in PAH.**Funds Raised:** INP**Changchun GeneScience Pharmaceutical Co., Ltd. (GenSci)**  
(SZSE:000661)**Categorical Listings:** Immunology, Oncology, Women's Health**Location:** Shanghai,  
China**Established:** 1997**Website:** [genscigroup.com/en](http://genscigroup.com/en)**Presenter:** Yuanfeng Xia,  
PhD, Executive Director**Corporate Partners:** INP**Funds Raised:** INP**Chimeric Therapeutics** (ASX:CHM)**Categorical Listings:** Cell Therapy, Hematology, Oncology**Location:** Carlton,  
Australia**Established:** 2020**Website:** [chimerictherapeutics.com](http://chimerictherapeutics.com)**Presenter:** Rebecca McQualter,  
PhD, CEO**Corporate Partners:** INP**Funds Raised:** INP

## **Chrysalis BioTherapeutics, Inc.**

**Categorical Listings:** Inflammation, Pulmonary, Regenerative Medicine

**Location:** Galveston,  
Texas United States

**Established:** 2012

**Website:** chrysbio.com

**Presenter:** Darrell H. Carney, PhD,  
President & CEO

**Corporate Partners:** Currently working with NIAID.

**Funds Raised:** Recently, \$500K Seed (Convertible Debt).  
Previously used non-dilutive NIH/BARDA grants/contracts  
for drug development (\$35M).

---

## **Cigma**

**Categorical Listings:** Cardiovascular, Other, Personalized Medicine

**Location:** Philadelphia,  
Pennsylvania United States

**Established:** 2020

**Website:** usecigma.com

**Presenter:** Josh Israel, CEO

**Corporate Partners:** INP

**Funds Raised:** INP

---

## **CNCure Co., Ltd.**

**Categorical Listings:** Oncology, Oncology Combination Therapy, Radiopharmaceuticals

**Location:** Hwasun-gun,  
South Korea

**Established:** 2019

**Website:** cncure.co.kr

**Presenter:** Jinbae Son,  
PhD, Managing Director

**Corporate Partners:** No corporate partners at this time.

**Funds Raised:** INP

## Coagulant Therapeutics

**Categorical Listings:** Hematology, Infectious Disease, Orphan/Rare Disease

**Location:** Berkeley,  
California, United States

**Corporate Partners:** No corporate partners at this time.

**Established:** 2019

**Funds Raised:** INP

**Website:** coagulanttherapeutics.com

**Presenter:** Terry Hermiston, PhD, CEO

---

## Coval Biopharma Co., Ltd.

**Categorical Listings:** Autoimmune, Inflammation, Platform Technology

**Location:** Shanghai,  
China

**Corporate Partners:** No corporate partners

**Established:** 2019

**Funds Raised:** \$20M to date

**Website:** coval-biopharma.com

**Presenter:** Hao Zhang, PhD,  
Founder & CEO

---

## CryoStasis Inc

**Categorical Listings:** Biomanufacturing, Cell Therapy

**Location:** Ottawa,  
Ontario Canada

**Corporate Partners:** Under NDA with Top 10 global  
biopharma companies.

**Established:** 2022

**Funds Raised:** \$6.3M in Seed round in 2022. Additionally,  
\$800K in government grants.

**Website:** cryostasis.ca

**Presenter:** Keith Millar,  
MBA, CEO & President

---

## **Cynata Therapeutics Pty Ltd.** (ASX:CYP)

**Categorical Listings:** Cell Therapy, Fibrosis, Immunology

**Location:** Cremorne,  
Australia

**Established:** 2011

**Website:** [cynata.com](http://cynata.com)

**Presenter:** Mathias Kroll,  
PhD, MBA, CBO

**Corporate Partners:** Strategic partnership with the University of Wisconsin-Madison and with Japanese firm Fujifilm. Cynata and Fujifilm are collaborating on the manufacture and scale-up of the Cymerus manufacturing process.

**Funds Raised:** Listed on the Australian stock exchange ASX (CYP).

---

## **Dx&Vx Co., Ltd** (KOSDAQ:180400)

**Categorical Listings:** Diagnostics, Immuno-oncology, Vaccines

**Location:** Seoul,  
South Korea

**Established:** 2001

**Website:** [dxvx.com](http://dxvx.com)

**Presenter:** Kyu-chan (Kevin) Kwon,  
PhD, CEO

**Corporate Partners:** The OVM-200 pipeline is under development in collaboration with Oxford Vacmedix, a sister company of Dx&Vx.

**Funds Raised:** INP

---

## **Eleva GmbH**

**Categorical Listings:** Endocrine/Metabolic, Immunology, Platform Technology

**Location:** Freiburg,  
Germany

**Established:** 1999

**Website:** [elevabiologics.com](http://elevabiologics.com)

**Presenter:** Bjoern Cochlovius,  
PhD, CEO

**Corporate Partners:** Strategic manufacturing partnership to be announced shortly.

**Funds Raised:** Current fund raise €120M plus €20M committed.

## **Empath Biosciences**

**Categorical Listings:** Drug Discovery, Machine Learning, Mitochondrial Therapeutic

**Location:** Nashville,  
Tennessee United States

**Established:** 2023

**Website:** [empathbio.com](http://empathbio.com)

**Presenter:** Michael Savona,  
MD, CEO & Co-Founder

**Corporate Partners:** No current corporate partners.

**Funds Raised:** The company has raised its first pre-Seed funding, and is actively raising capital.

---

## **Enhanc3D Genomics Ltd**

**Categorical Listings:** Autoimmune, Big Data, Platform Technology

**Location:** Cambridge,  
United Kingdom

**Established:** 2020

**Website:** [enhanc3dgenomics.com](http://enhanc3dgenomics.com)

**Presenter:** Hazel Jones, PhD, CEO

**Corporate Partners:** The company was awarded an immunology J&J QuickFire Challenge and has completed a commercial contract with a major CDMO.

**Funds Raised:** £10M in 2022 for Series A bringing the total raise for the company to £11.75M.

---

## **Epion Therapeutics, Inc.**

**Categorical Listings:** Ophthalmic

**Location:** Burlington,  
Massachusetts United States

**Established:** 2012

**Website:** [epiontx.com](http://epiontx.com)

**Presenter:** Michael Webb, MA, CEO

**Corporate Partners:** None

**Funds Raised:** \$32M Series A in 2022.



## **ExCellThera Inc.**

**Categorical Listings:** Cell Therapy, Oncology, Platform Technology

**Location:** Montreal,  
Quebec Canada

**Established:** 2015

**Website:** excellthera.com

**Presenter:** David Millette, CEO

**Corporate Partners:** The company collaborates with, and outlicenses its UM171 molecule and platform technology in adjacent fields and applications to, bio-pharma partners, including Astellas and SR-Tiget.

**Funds Raised:** INP

---

## **FibroBiologics (NASDAQ:FBLG)**

**Categorical Listings:** Cell Therapy, Longevity/Healthspan/Diseases of Aging, Regenerative Medicine

**Location:** Houston,  
Texas United States

**Established:** 2021

**Website:** fibrobiologics.com

**Presenter:** Pete O’Heeron,  
Founder & CEO

**Corporate Partners:** Currently looking for collaboration partners on all pipeline targets.

**Funds Raised:** Since inception, more than \$50M.

---

## **Gain Therapeutics, Inc. (NYSE:GANX)**

**Categorical Listings:** Artificial Intelligence (AI), CNS/Neurological, Drug Discovery

**Location:** Bethesda,  
Maryland United States

**Established:** 2017

**Website:** gaintherapeutics.com

**Presenter:** Gene Mack,  
MBA, CFO & Interim CEO

**Corporate Partners:** INP

**Funds Raised:** INP

## Galena Innovations, Inc.

**Categorical Listings:** Other, Reproductive Medicine, Women's Health

**Location:** Boise,  
Idaho United States

**Established:** 2019

**Website:** galenainnovations.com

**Presenter:** Ashley Crafton,  
MBEE, CEO & Founder

**Corporate Partners:** The company is developing corporate partners at this time.

**Funds Raised:** \$190K of non-dilutive funding, now raising a Seed round of \$3.6M to \$5.4M and have raised \$275K so far.

## GelMEDIX, Inc.

**Categorical Listings:** Drug Delivery, Ophthalmic, Regenerative Medicine

**Location:** Cambridge,  
Massachusetts United States

**Established:** 2020

**Website:** gelmedix.com

**Presenter:** Max Cotler, PhD, COO

**Corporate Partners:** Received the LabCentral Golden Ticket from AbbVie and investment from HTL biotechnologies.

**Funds Raised:** \$10M through convertible notes, \$600K from U.S. DoD. Currently raising \$1.5M to IND or \$50M to clinical PoC.

## GenAssist Ltd

**Categorical Listings:** CRISPR, Drug Delivery, Orphan/Rare Disease

**Location:** Suzhou,  
China

**Established:** 2020

**Website:** genassisttx.com

**Presenter:** Chunyan (Chelsie) He, CEO

**Corporate Partners:** INP

**Funds Raised:** \$25M

## **GeneCapture, Inc.**

**Categorical Listings:** Diagnostics, Infectious Disease, Platform Technology

**Location:** Huntsville,  
Alabama United States

**Established:** 2009

**Website:** [genecapture.com](http://genecapture.com)

**Presenter:** Peggy Sammon, CEO

**Corporate Partners:** U.S. company selected for cartridge manufacturing. Strategic discussions begun with clinics and government customers. Contracts underway with Defense Health Agency and Defense Threat Reduction Agency.

**Funds Raised:** \$18M to date; \$12M from Department of Defense non-dilutive development contracts, \$6M from Angel and regional VCs.

---

## **GeneTether Therapeutics Inc. (CNSX:GTTX)**

**Categorical Listings:** Oncology

**Location:** Kelowna,  
British Columbia Canada

**Established:** 2018

**Website:** [genetether.com](http://genetether.com)

**Presenter:** Jonathan Rothman,  
PhD, CSO

**Corporate Partners:** INP

**Funds Raised:** \$6M

---

## **Genvara Biopharma, Inc.**

**Categorical Listings:** Cardiovascular, Personalized Medicine, Pharmacogenetics

**Location:** Westminster,  
Colorado United States

**Established:** 2024

**Website:** [genvarabiopharma.com](http://genvarabiopharma.com)

**Presenter:** Thomas (Tom) Keuer,  
MS, President & CEO

**Corporate Partners:** Currently seeking corporate partners.

**Funds Raised:** Currently funded by Founders. Seeking new investors and/or partners to support a Phase 3 pivotal trial.

## **GeoVax Labs, Inc. (NASDAQ:GOVX)**

**Categorical Listings:** Immuno-oncology, Infectious Disease, Vaccines

**Location:** Smyrna,  
Georgia United States

**Established:** 2001

**Website:** geovax.com

**Presenter:** David Dodd,  
MS, Chairman & CEO

**Corporate Partners:** BARDA clinical trial support for GEO-CM04S1.

**Funds Raised:** >\$20M equity capital during 2024. Secured BARDA funding of nearly \$400M for clinical trial support.

## **Gluetacs Therapeutics (Shanghai) Co., Ltd.**

**Categorical Listings:** Drug Discovery, Immunology, Oncology

**Location:** Pudong District,  
China

**Established:** 2020

**Website:** gluetacs.com

**Presenter:** Rob Sons, PhD, Head,  
Business Development, North America

**Corporate Partners:** The company's pipeline and platform are wholly owned.

**Funds Raised:** \$32M cumulatively since founding in 2020, most recently closing a Series A1 (\$8.4M) in June 2024.

## **Guangdong Fapon Biopharma Inc.**

**Categorical Listings:** Antibodies, Autoimmune, Immuno-oncology

**Location:** Lexington,  
Massachusetts United States

**Established:** 2015

**Website:** faponbiopharma.com

**Presenter:** Max Wang,  
Business Development

**Corporate Partners:** The company is looking for global development partners for its pipeline with a focus on the cytokine(IL10) fusion programs.

**Funds Raised:** INP

## Help Therapeutics Co. Ltd.

**Categorical Listings:** Cardiovascular, Cell Therapy, Regenerative Medicine

**Location:** Nanjing,  
China

**Established:** 2016

**Website:** en.helptherapeutics.com

**Presenter:** Jiaxian (Eugene) Wang,  
PhD, Founder & CEO

**Corporate Partners:** Actively seeking licensing and/or co-development partners.

**Funds Raised:** HelpTx has secured three rounds of funding - a total of \$35M.

---

## Hemay Pharmaceuticals

**Categorical Listings:** Immuno-oncology, Inflammation, Oncology

**Location:** Tianjin,  
China

**Established:** 2002

**Website:** hemaypharmaceuticals.com

**Presenter:** Richard Jones, DM,  
Global CMO

**Corporate Partners:** None to date.

**Funds Raised:** INP

---

## Huonslab Co., Ltd

**Categorical Listings:** Antibodies, Mitochondrial Therapeutic

**Location:** Seongnam si,  
South Korea

**Established:** 2018

**Website:** huonslab.com

**Presenter:** YoungSun Lee, MD, CBO

**Corporate Partners:** The company has embarked on a worldwide collaboration effort and are in talks with several firms across the U.S., Europe, and other regions to establish licensing agreements and similar partnerships.

**Funds Raised:** Huons Lab, a subsidiary of Huons Global, is being expanded with comprehensive backing from its parent company.

## Hyundai Bioscience Co. Ltd. (KOSDAQ:048410)

**Categorical Listings:** CNS/Neurological, Infectious Disease, Oncology Combination Therapy

**Location:** Seoul,  
South Korea

**Corporate Partners:** Not Disclosed

**Established:** 2000

**Funds Raised:** Publicly traded company

**Website:** hyundaibioscience.com

**Presenter:** Jason Kim, MCS, President,  
Hyundai Bioscience USA Inc.

---

## IASO Biotechnology

**Categorical Listings:** Hematology, Immunology, Neurology

**Location:** Nanjing,  
China

**Corporate Partners:** IASO Bio has formed global collaborations and licensing agreements with top cell therapy companies, including Sana Therapeutics, Cabaletta Bio, and Umoja Biopharma to develop products for oncology and autoimmune indications.

**Established:** 2017

**Website:** iasobio.com

**Presenter:** Alan Fu, PhD, MS, CFO

**Funds Raised:** More than \$200M over the years.

---

## iBio, Inc. (NYSE:IBIO)

**Categorical Listings:** Antibodies, Drug Discovery, Machine Learning

**Location:** San Diego,  
California United States

**Corporate Partners:** Through a strategic partnership with AstralBio, the company is developing molecules for obesity, diabetes, and heart disease.

**Established:** 2008

**Funds Raised:** INP

**Website:** ibioinc.com

**Presenter:** Martin Brenner,  
DVM, PhD, CEO & CSO

## iBody Inc.

**Categorical Listings:** Antibodies, Drug Discovery, Machine Learning

**Location:** Nagoya,  
Japan

**Established:** 2018

**Website:** [ibody.co.jp/en](http://ibody.co.jp/en)

**Presenter:** Yo (Max) Amakusa,  
MBA, CEO

**Corporate Partners:** Capital and business alliance with TAUNS Laboratories Inc.

**Funds Raised:** \$3.7M with \$0.7M in 2018, \$1M in 2020 and \$2M in 2023.

---

## Ichnos Glenmark Innovation (IGI)

**Categorical Listings:** Antibodies, Autoimmune, Immuno-oncology

**Location:** New York,  
New York United States

**Established:** 2019

**Website:** [iginnovate.com](http://iginnovate.com)

**Presenter:** Cyril Konto,  
MD, President & CEO

**Corporate Partners:** ISB 880 (anti-IL1RAP mAb) with Almirall, ISB 830 (anti-OX40 mAb) with Astria Therapeutics, and the oncology portfolio with Glenmark Pharmaceuticals showcase IGI's collaborations driving innovation in therapeutic development.

**Funds Raised:** Not disclosed

---

## Ignota Labs

**Categorical Listings:** Artificial Intelligence (AI), Bioinformatics, Endocrine/Metabolic

**Location:** Cambridge,  
United Kingdom

**Established:** 2021

**Website:** [ignotalabs.ai](http://ignotalabs.ai)

**Presenter:** Sam Windsor, MBA, CEO

**Corporate Partners:** The company has a partnership with Sanofi.

**Funds Raised:** £800K in private capital to date, plus £300K in grant funding. Currently mid-way through closing a £5M Seed round.

## IMBiologics

**Categorical Listings:** Antibodies, Immuno-oncology, Platform Technology

**Location:** Suwon,  
South Korea

**Established:** 2020

**Website:** imbiologics.com

**Presenter:** Ji Yeon Hong,  
PhD, Head, Business Development

**Corporate Partners:** Lead assets, IMB-101 and IMB-102 are out-licensed to Navigator Medicine (WW excluding Asia) and Huadong Medicine (Asia excluding Korea) in 2024.

**Funds Raised:** Series A of ₩17B in 2021 and Series B of ₩20B completed in 2023.

## Immunis, Inc.

**Categorical Listings:** Longevity/Healthspan/Diseases of Aging, Musculoskeletal, Regenerative Medicine

**Location:** Irvine,  
California United States

**Established:** 2019

**Website:** immunisbiomedical.com

**Presenter:** Hans Keirstead,  
PhD, Chairman of the Board

**Corporate Partners:** Immunis has no corporate partners, but several academic collaborators at the University of Utah, UC Irvine, UC Berkeley and UC Davis.

**Funds Raised:** \$13M

## Immuto Scientific

**Categorical Listings:** Drug Discovery, Oncology, Platform Technology

**Location:** Madison,  
Wisconsin United States

**Established:** 2021

**Website:** immutotx.com

**Presenter:** Faraz Choudhury,  
PhD, CEO

**Corporate Partners:** 30+ partnership projects completed.

**Funds Raised:** \$7M



## **IN8bio, Inc** (NASDAQ:INAB)

**Categorical Listings:** Cell Therapy, Immuno-oncology, Oncology

**Location:** New York,  
New York United States

**Corporate Partners:** None

**Established:** 2016

**Funds Raised:** \$134M

**Website:** in8bio.com

**Presenter:** William (Will) Ho,  
MBA, CEO

---

## **Infinитopes Precision Immunomics**

**Categorical Listings:** Artificial Intelligence (AI), Immuno-oncology, Personalized Medicine

**Location:** Oxford,  
United Kingdom

**Corporate Partners:** The company has shortlisted big pharma partners and is currently in talks. Open to discussions with other oncology leaders, to setup global/regional collaborations, in vaccines and alternative modalities.

**Established:** 2021

**Website:** infinitopes.com

**Presenter:** Jonathan Kwok,  
MD, PhD, CEO

**Funds Raised:** \$20M, 25% won as prestigious nondilutive awards. Oversubscribed pre-Seed rounds led by highly-rated startup, TechBio & oncology funds.

---

## **InkSpace Imaging, Inc.**

**Categorical Listings:** Other, Platform Technology

**Location:** Pleasanton,  
California United States

**Corporate Partners:** Currently Siemens, GE, Philips. Fujifilm and Canon interested too.

**Established:** 2016

**Funds Raised:** INP

**Website:** inkpaceimaging.com

**Presenter:** Peter Fischer,  
PhD, CEO

**IO Biotech, Inc.** (NASDAQ:IOBT)**Categorical Listings:** Immuno-oncology**Location:** Copenhagen,  
Denmark**Established:** 2014**Website:** iobiotech.com**Presenter:** Mai-Britt Zocca,  
PhD, MSc, CEO**Corporate Partners:** The company's clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab.**Funds Raised:** \$115.1M at IPO in 2021; \$75M in private placement financing in 2023.**IVIEW Therapeutics Inc.****Categorical Listings:** Drug Delivery, Gene Therapy, Ophthalmic**Location:** Cranbury,  
New Jersey United States**Established:** 2015**Website:** iviewtherapeutics.com**Presenter:** Bo Liang, PhD, MBA, CEO**Corporate Partners:** IVW-1001 was developed through collaboration with Orinda Pharma in California and Prof. Eddie Wei, Emeritus Professor at UC Berkeley.**Funds Raised:** \$40M in three rounds of financing and target B round financing of \$40M to advance programs in Phase 3 trials.**Jaguar Health, Inc.** (NASDAQ:JAGX)**Categorical Listings:** Gastrointestinal, Oncology, Orphan/Rare Disease**Location:** San Francisco,  
California United States**Established:** 2013**Website:** jaguar.health**Presenter:** Lisa Conte, MS, MBA,  
Founder, CEO & President**Corporate Partners:** The company is open to partnership discussions for development and commercialization of specific Jaguar human and animal prescription drug candidates.**Funds Raised:** INP

## **JW Pharmaceutical Corporation (KRX:001060)**

**Categorical Listings:** Dermatology, Endocrine/Metabolic, Oncology

**Location:** Gwacheon-si,  
South Korea

**Corporate Partners:** Baxter, Chugai, CSL Vifor, Kissei,  
Kowa, Otsuka, Sandoz, Shionogi, Abbott, CHEST, Fujifilm

**Established:** 1945

**Funds Raised:** Over \$50M invested. Seeking \$10–30M,  
strategic/financial, for Phase 1 in solid cancer or Phase  
1-readiness research in obesity.

**Website:** jw-pharma.co.kr

**Presenter:** Sunyoung Kim,  
Head, R&D Strategic Assessment Team

## **Kanglin Biotec (Hangzhou) Co., Ltd.**

**Categorical Listings:** Gene Therapy, Hematology, Orphan/Rare Disease

**Location:** Hangzhou,  
China

**Corporate Partners:** Hematology Hospital of the Chinese  
Academy of Medical Sciences (Institute of Hematology,  
Chinese Academy of Medical Sciences), Ruijin Hospital,  
Tianhai Future (Tianjin) Biopharmaceutical Co.

**Established:** 2015

**Website:** kanglinbio.com

**Funds Raised:** ~\$30M since 2015.

**Presenter:** Difei Yang,  
PhD, MBA, COO & CFO

## **Kinea Bio, Inc.**

**Categorical Listings:** Gene Therapy, Musculoskeletal, Orphan/Rare Disease

**Location:** Edmonds,  
Washington United States

**Corporate Partners:** The company's lead program in  
Duchenne muscular dystrophy is being developed in  
partnership with Ultragenyx Pharmaceutical Inc. (CA).

**Established:** 2020

**Website:** kineabio.com

**Funds Raised:** A total of ~\$3M to date, including \$615K  
from Seed investors and \$2.45M in grants and pharma  
partnership.

**Presenter:** Martin (Casey) K. Childers,  
DO, PhD, CEO

## Lahjavidia, Inc.

**Categorical Listings:** Drug Discovery, Oncology, Platform Technology

**Location:** Colorado Springs,  
Colorado United States

**Established:** 2019

**Website:** lahjavidia.com

**Presenter:** Lyle Small, CEO

**Corporate Partners:** None to date.

**Funds Raised:** \$2.2M of private investment. \$600K of non-dilutive 501c3 donations.

## Lipo-Immuno Tech, LLC

**Categorical Listings:** Cell Therapy, Mitochondrial Therapeutic, Oncology

**Location:** Mount Pleasant,  
South Carolina United States

**Established:** 2018

**Website:** lipo-immunotech.com

**Presenter:** Shikhar Mehrotra,  
PhD, Co-Founder & CSO

**Corporate Partners:** The company did not seek any corporate partners until now.

**Funds Raised:** For the Cell Thera Pro development, \$400K between 2021-2022, and about \$5M between 2023-2024 in non-dilutive funds.

## Livionex Inc.

**Categorical Listings:** Dermatology, Inflammation, Ophthalmic

**Location:** Los Gatos,  
California United States

**Established:** 2009

**Website:** livionex.com

**Presenter:** Amit Goswamy, MBA, CEO

**Corporate Partners:** Looking at corporate development partnerships for Phase 3 ophthalmic trial for treatment of early/moderate cataracts.

**Funds Raised:** \$4.2M from high-net-worth investors. Received \$1.3M in NIH/DoD grants.

## **Livivos Inc**

**Categorical Listings:** Diagnostics, Fibrosis, Gastrointestinal

**Location:** San Diego,  
California United States

**Established:** 2018

**Website:** livivos.com

**Presenter:** Pablo Prado, PhD, CEO

**Corporate Partners:** Received funds from Pfizer.

**Funds Raised:** \$2.6M with 14 convertible notes, and funds from founder, NIH, and Pfizer.

## **Lmito Therapeutics Inc.**

**Categorical Listings:** Fibrosis, Immunology, Orphan/Rare Disease

**Location:** Yongin-si,  
South Korea

**Established:** 2017

**Website:** lmito.com

**Presenter:** Wheeseong Lee,  
PhD, CEO

**Corporate Partners:** INP

**Funds Raised:** INP

## **Longeveron Inc. (NASDAQ:LGVN)**

**Categorical Listings:** Cell Therapy, Longevity/Healthspan/Diseases of Aging, Regenerative Medicine

**Location:** Miami,  
Florida United States

**Established:** 2014

**Website:** longeveron.com

**Presenter:** Wa'el Hashad, MBA, CEO

**Corporate Partners:** Stem cell therapy candidate Lomecel-B being developed as a potential adjunct therapy for HLHS at 12 premiere infant and children's treatment institutions across the country.

**Funds Raised:** Over \$100M. Cash & cash equivalents at 9/30/2024 were \$22.8M, expected to fund operations thru Q4 2025.

## **LoxiGen, Inc.**

**Categorical Listings:** Drug Discovery, Fibrosis, Oncology

**Location:** Charleston,  
South Carolina United States

**Corporate Partners:** The company does not have partners yet.

**Established:** 2021

**Funds Raised:** INP

**Website:** loxigen.com

**Presenter:** Ozgur Sahin,  
PhD, MSc, Founder & President

---

## **LPOXY Therapeutics, Inc**

**Categorical Listings:** Gastrointestinal, Infectious Disease

**Location:** Platte City,  
Missouri United States

**Corporate Partners:** LPOXY has no current pharmaceutical partners, but is currently in negotiations.

**Established:** 2020

**Funds Raised:** \$1.25M in Angel funds and is initiating its \$40M Series A for pivotal Phase 2.

**Website:** lpoxy.com

**Presenter:** Larry Sutton,  
MD, PhD, President

---

## **MAIA Biotechnology, Inc. (NYSE:MAIA)**

**Categorical Listings:** Oncology, Oncology Combination Therapy

**Location:** Chicago,  
Illinois United States

**Corporate Partners:** Clinical supply agreement with Regeneron for THIO-101 clinical trial.

**Established:** 2018

**Funds Raised:** YTD 2024 more than \$15M in PIPE and ATM.

**Website:** maiaibiotech.com

**Presenter:** Vlad Vitoc,  
MD, MBA, Founder & CEO

## **MEKanistic Therapeutics, Inc.**

**Categorical Listings:** Oncology

**Location:** Minneapolis,  
Minnesota United States

**Established:** 2015

**Website:** mekanistic.com

**Presenter:** Judith Leopold,  
PhD, CSO

**Corporate Partners:** MEKanistic is a member of the NCI's NExT program, designed to accelerate the translation of scientific discoveries into tangible therapeutic options for cancer patients.

**Funds Raised:** To date, MEKanistic has been funded by a combination of \$10M in non-dilutive funding, and \$5M in equity financing.

---

## **Mesoblast Limited (ASX:MSB)**

**Categorical Listings:** Cardiovascular, Cell Therapy, Inflammation

**Location:** New York,  
New York United States

**Established:** 2004

**Website:** mesoblast.com

**Presenter:** Silviu Itescu, MD, CEO

**Corporate Partners:** Grunenthal for chronic lower back pain in EU/Latin America.

**Funds Raised:** >\$500M

---

## **Microvascular Therapeutics, Inc**

**Categorical Listings:** Cardiovascular, CNS/Neurological, Oncology

**Location:** Tucson,  
Arizona United States

**Established:** 2014

**Website:** mvtpharma.com

**Presenter:** Evan Unger, MD, CEO

**Corporate Partners:** No partner identified yet, in discussion with many.

**Funds Raised:** \$12M non-diluting funds, \$3.5M capital investment, \$5M in kind.

## **MindImmune Therapeutics Inc.**

**Categorical Listings:** CNS/Neurological, Drug Discovery, Inflammation

**Location:** Kingston,  
Rhode Island United States

**Corporate Partners:** INP

**Funds Raised:** \$19.4M to date.

**Established:** 2016

**Website:** mindimmune.com

**Presenter:** Stevin H. Zorn,  
PhD, President & CEO

---

## **MitoRx Therapeutics Limited**

**Categorical Listings:** Endocrine/Metabolic, Mitochondrial Therapeutic, Musculoskeletal

**Location:** Didcot,  
United Kingdom

**Corporate Partners:** None disclosable.

**Funds Raised:** \$7M to date.

**Established:** 2021

**Website:** mitorxtherapeutics.com

**Presenter:** Jonathan (Jon) David Rees,  
PhD, CEO

---

## **MitrAssist Lifesciences Limited**

**Categorical Listings:** Cardiovascular, Diagnostics

**Location:** Shanghai,  
China

**Corporate Partners:** Pipelines are being developed by the company.

**Funds Raised:** \$25M in 2017 Round A; \$70M in 2020 Round B; nearly \$100M in 2023 Round C.

**Established:** 2017

**Website:** mp.weixin.qq.com/s/  
s3wqD-7D4XcPzGRTdc0blg

**Presenter:** Li Wang, CEO



## MKC Biotherapeutics, Inc.

**Categorical Listings:** Cell Therapy, Longevity/Healthspan/Diseases of Aging, Regenerative Medicine

**Location:** Jacksonville,  
Florida United States

**Established:** 2024

**Website:** mkcbiotherapeutics.com

**Presenter:** Madhusudan (Vik) Peshwa,  
PhD, CEO

**Corporate Partners:** MKC has license to IP, Technology and access to all data from Stempeutics Research Private Limited (Bengaluru, India) for development of Drug Products for all indications in U.S. and Europe.

**Funds Raised:** INP

## Mobius Scientific, Inc.

**Categorical Listings:** Ophthalmic, Orphan/Rare Disease, Platform Technology

**Location:** Washington,  
District of Columbia United States

**Established:** 2021

**Website:** mobius-scientific.com

**Presenter:** Nehal Mehta,  
MD, MSCE, CEO

**Corporate Partners:** Mobius is a JLABS DC and JLABS Singapore portfolio company, working with three other pharma groups on co-development of future indications which are in legal document phase currently.

**Funds Raised:** INP

## Mogling Bio Inc

**Categorical Listings:** Hematology, Immuno-oncology, Longevity/Healthspan/Diseases of Aging

**Location:** Wilmington,  
Delaware United States

**Established:** 2022

**Website:** moglingbio.com

**Presenter:** Jürgen Reeß, MD, CEO

**Corporate Partners:** INP

**Funds Raised:** Raising approx. \$10M in order to perform IND package.

## MOLCURE Inc.

**Categorical Listings:** Antibodies, Artificial Intelligence (AI), Platform Technology

**Location:** Kawasaki,  
Japan

**Established:** 2013

**Website:** molcure.com

**Presenter:** Satoshi Tamaki,  
PhD, CEO & CSO

**Corporate Partners:** The company's lab processing operations are run primarily by HealthQuest Esoterics, California.

**Funds Raised:** More than \$10M and revenues from partnerships with 11 companies.

---

## Multimeric Biotherapeutics, Inc.

**Categorical Listings:** Immuno-oncology, Infectious Disease, Vaccines

**Location:** La Jolla,  
California United States

**Established:** 2008

**Website:** multimericbio.com

**Presenter:** Richard Kornbluth,  
MD, PhD, President & CSO

**Corporate Partners:** Seeking partnering opportunities.

**Funds Raised:** \$4M from Angels, the founders, and Government grants.

---

## MultiOmic Health Limited

**Categorical Listings:** Artificial Intelligence (AI), Drug Discovery, Endocrine/Metabolic

**Location:** London,  
United Kingdom

**Established:** 2021

**Website:** multiomic.health

**Presenter:** Robert Thong, CEO

**Corporate Partners:** Research collaborations with two UK, one Spanish and one Finnish academic healthcare providers. Seeking pharma collaborations to discover novel therapeutics or to reposition/extend partners' existing assets to new indications.

**Funds Raised:** Circa \$10M to date, most recently a \$6.2M Seed round in 2023.

## **Mustbio Co., Ltd.**

**Categorical Listings:** Infectious Disease, Oncology

**Location:** Seoul,  
South Korea

**Corporate Partners:** The company is currently seeking partners for its pipelines, MB5029 and MB4.

**Established:** 2021

**Funds Raised:** INP

**Website:** mustbio.com/en

**Presenter:** Jun Eui Park,  
PhD, VP, New Drug Evaluation

---

## **Nalu Bio**

**Categorical Listings:** Drug Discovery, Inflammation, Neuropathy/Pain

**Location:** San Francisco,  
California United States

**Corporate Partners:** PIPA, Sanobiotec

**Established:** 2019

**Funds Raised:** \$14M via Seed round and Series A.

**Website:** nalubio.com

**Presenter:** Caitlyn Krebs,  
CEO & Co-Founder

---

## **Nammi Therapeutics, Inc.**

**Categorical Listings:** Immuno-oncology, Oncology Combination Therapy, Platform Technology

**Location:** Los Angeles,  
California United States

**Corporate Partners:** Actively seeking.

**Established:** 2018

**Funds Raised:** More than \$40M to date plus over \$5M in non-dilutive funding.

**Website:** nammirx.com

**Presenter:** David Stover, PhD, CEO

## Nanopath

**Categorical Listings:** Diagnostics, Infectious Disease, Women's Health

**Location:** Cambridge,  
Massachusetts United States

**Corporate Partners:** INP

**Established:** 2019

**Funds Raised:** More than \$15M, with \$11M in investments and \$4M+ in grants.

**Website:** nanopath.com

**Presenter:** Alison Burklund,  
PhD, Co-Founder

---

## NanoViricides, Inc. (NYSE:NNVC)

**Categorical Listings:** Infectious Disease, Orphan/Rare Disease, Pulmonary

**Location:** Shelton,  
Connecticut United States

**Corporate Partners:** Seeking partnerships.

**Established:** 2005

**Funds Raised:** More than \$150M since 2005.

**Website:** nanoviricides.com

**Presenter:** Anil R. Diwan,  
PhD, President & Chairman

---

## NeuExcell Therapeutics Inc

**Categorical Listings:** CNS/Neurological, Gene Therapy, Regenerative Medicine

**Location:** Philadelphia,  
Pennsylvania United States

**Corporate Partners:** Looking for partnership on both NXL-004 and NXL-001. NXL-002 was in a partnership for HD with Spark Therapeutics in 2021-2024.

**Established:** 2016

**Funds Raised:** \$36M from investors, including \$30M from VCs and \$6M from individuals.

**Website:** neuexcell.com

**Presenter:** Xi Qin, MBA, CEO

---

## **Novigenix SA**

**Categorical Listings:** Artificial Intelligence (AI), Immuno-oncology, Platform Technology

**Location:** Epalinges,  
Switzerland

**Corporate Partners:** INP

**Funds Raised:** More than \$20M.

**Established:** 2014

**Website:** novigenix.com

**Presenter:** Brian Hashemi, PhD,  
MBA, Executive Chairman & CEO

---

## **Nutshell Therapeutics**

**Categorical Listings:** Artificial Intelligence (AI), Drug Discovery, Platform Technology

**Location:** Shanghai,  
China

**Corporate Partners:** Work in process.

**Funds Raised:** Cumulative \$75M.

**Established:** 2011

**Website:** allonutshell.com

**Presenter:** Kevin Xie, CBO

---

## **NuvOx Therapeutics**

**Categorical Listings:** CNS/Neurological, Oncology, Platform Technology

**Location:** Tucson,  
Arizona United States

**Corporate Partners:** Currently seeking regional partnership.

**Funds Raised:** \$17.5M, out of which \$7M closed in 2023.

**Established:** 2008

**Website:** nuvoxpharma.com

**Presenter:** Rong Wang,  
MBA, MSE, President

## OCMS Bio LLC

**Categorical Listings:** Antibodies, Drug Discovery, Infectious Disease

**Location:** King of Prussia,  
Pennsylvania United States

**Corporate Partners:** Lead pipeline is currently in discussions for partnership.

**Established:** 2021

**Funds Raised:** \$2M

**Website:** ocms.bio

**Presenter:** Paul Halpern, CEO

---

## Oncolytics Biotech INC. (NASDAQ:ONCY)

**Categorical Listings:** Immuno-oncology, Oncology

**Location:** Calgary,  
Alberta Canada

**Corporate Partners:** Clinical collaborations with Roche and Pfizer.

**Established:** 1999

**Funds Raised:** More than \$400M since the creation of the company.

**Website:** oncolyticsbiotech.com/about-us

**Presenter:** Christophe Degois,  
MBA, VP, Business Development

---

## Ordaos

**Categorical Listings:** Antibodies, Artificial Intelligence (AI), Drug Discovery

**Location:** New York,  
New York United States

**Corporate Partners:** Multiple top pharma, FatiAbGen, Yatiri Bio, Quercus

**Established:** 2019

**Funds Raised:** \$20M in Seed funding to date.

**Website:** ordaos.bio

**Presenter:** David Longo, MS, CEO

---

## Ori Biotech

**Categorical Listings:** Biomanufacturing, Cell Therapy, Gene Therapy

**Location:** London,  
United Kingdom

**Established:** 2015

**Website:** oribiotech.com

**Presenter:** Jason Foster, MBA, CEO

**Corporate Partners:** Ori Biotech partnered with CTMC (a joint venture between Resilience and MD Anderson), Charles River Laboratories, and others to accelerate their progress towards the scalable production of novel cell therapies.

**Funds Raised:** INP

---

## Origenis GmbH

**Categorical Listings:** CNS/Neurological, Drug Discovery, Oncology Combination Therapy

**Location:** Planegg,  
Germany

**Established:** 2005

**Website:** origenis.com

**Presenter:** Andreas Tremel, PhD, COO

**Corporate Partners:** Origenis currently has no partners.

**Funds Raised:** Origenis is a private financed company that founded Neuron23 according to its business strategy. Neuron23 is financed over \$140M.

---

## Osmol Therapeutics, Inc.

**Categorical Listings:** Neuropathy, Oncology

**Location:** New Haven,  
Connecticut United States

**Established:** 2017

**Website:** osmoltherapeutics.com

**Presenter:** Bob Linke,  
MBA, President & CEO

**Corporate Partners:** Seeking corporate partners in U.S., EU and China interested in commercial rights to OSM-0205.

**Funds Raised:** INP

## Owl Therapeutics

**Categorical Listings:** Artificial Intelligence (AI), CNS/Neurological, Mitochondrial Therapeutic

**Location:** San Antonio,  
Texas United States

**Established:** 2023

**Website:** owltherapeutics.com

**Presenter:** William (Will) Haskins,  
PhD, MS, CEO & Co-Founder

**Corporate Partners:** Through partnership with Gryphon Bio, Owl's pipeline is powered by novel diagnostic blood tests for enrichment and tracking of responding patients. Owl's pipeline is also powered by novel AI technologies.

**Funds Raised:** \$13.6M in non-dilutive funding accumulated over the past 5 years from NIH and DoD for Gryphon.

## PairX Bio

**Categorical Listings:** Antibodies, Bioinformatics, Immuno-oncology

**Location:** Singapore

**Established:** 2020

**Website:** pairxbio.com

**Presenter:** David Epstein,  
PhD, President & CEO

**Corporate Partners:** Confidential

**Funds Raised:** \$9.8M

## Pan Cancer T B.V.

**Categorical Listings:** Cell Therapy, Immuno-oncology, Oncology

**Location:** Rotterdam,  
Netherlands

**Established:** 2000

**Website:** pancancer-t.com

**Presenter:** Rachel Abbott, PhD, CEO

**Corporate Partners:** The process and analytical development of Pan Cancer T's lead cell therapy product, PCT1:CO-STIM, is being performed in partnership with NecstGen, a qualified CDMO.

**Funds Raised:** ~€8.9M to date in venture capital funding, plus ~€2.25M on in grants (awarded in partnership with Erasmus MC).



## **Path Fertility (FKA: Inherent Biosciences)**

**Categorical Listings:** Diagnostics, Epigenetics, Reproductive Medicine

**Location:** Salt Lake City,  
Utah United States

**Established:** 2019

**Website:** inherentbio.com

**Presenter:** Andy Olson, MBA, CEO

**Corporate Partners:** The company's reproductive health pipeline is being developed in partnership with US Fertility and Boston IVF.

**Funds Raised:** \$6.6M with one third as non-dilutive funding.

---

## **PDX Pharmaceuticals, Inc.**

**Categorical Listings:** Drug Delivery, Immuno-oncology, Platform Technology

**Location:** Portland,  
Oregon United States

**Established:** 2010

**Website:** pdxpharm.com

**Presenter:** Worapol Ngamcherdtrakul,  
PhD, Head, Research & COO

**Corporate Partners:** Not available yet, but open to partnerships.

**Funds Raised:** Over \$13.5M; with over \$10M in grants from the NIH and \$3.5M in Seed investment.

---

## **Perseo pharma AG**

**Categorical Listings:** Endocrine/Metabolic, Gastrointestinal, Orphan/Rare Disease

**Location:** Muttens,  
Switzerland

**Established:** 2019

**Website:** perseo-pharma.com

**Presenter:** Yves Dudal, PhD, CEO

**Corporate Partners:** Nestlé Health Science

**Funds Raised:** CHF 7M

## **Perspective Therapeutics, Inc. (NYSE:CATX)**

**Categorical Listings:** Drug Discovery, Oncology, Radiopharmaceuticals

**Location:** Seattle,  
Washington United States

**Corporate Partners:** Clinical trial collaboration agreement  
with Bristol Myers Squibb.

**Established:** 2004

**Funds Raised:** Approx. \$300M in 1H 2024.

**Website:** [perspectivetherapeutics.com](http://perspectivetherapeutics.com)

**Presenter:** Thijs Spoor, MBA, CEO

---

## **PG Pharma**

**Categorical Listings:** Endocrine/Metabolic, Inflammation, Neuropathy/Pain

**Location:** Southfield,  
Missouri United States

**Corporate Partners:** INP

**Established:** 2019

**Funds Raised:** Just under £2.5M.

**Website:** [pgpharma.co](http://pgpharma.co)

**Presenter:** Steve Goldner, CEO

---

## **Phecda Medicine Co., Ltd.**

**Categorical Listings:** Autoimmune, CNS/Neurological, Mitochondrial Therapeutic

**Location:** Hangzhou,  
China

**Corporate Partners:** Currently all pipelines  
are the company's proprietary assets. The  
company is seeking partnership.

**Established:** 2021

**Funds Raised:** INP

**Website:** [phecdamed.com](http://phecdamed.com)

**Presenter:** Mengyang Fan, PhD,  
Director, Medicinal Chemistry

## **Pilatus Biosciences**

**Categorical Listings:** Immunology, Oncology

**Location:** Lausanne,  
Switzerland

**Established:** 2022

**Website:** pilatusbio.com

**Presenter:** Raven Lin,  
PhD, MBA, CEO

**Corporate Partners:** Collaboration with Le Centre hospitalier universitaire vaudois (CHUV) and Weill Cornell Medicine - Cornell University.

**Funds Raised:** Garnered investments of approximately \$4.5M by 2024 Q3.

---

## **Polymed Biopharmaceuticals, Inc.**

**Categorical Listings:** Immunology, Inflammation, Oncology

**Location:** Hangzhou,  
China

**Established:** 2019

**Website:** polymedbiopharma.com/en

**Presenter:** Brent Meadows, MBA, CBO

**Corporate Partners:** Polymed is a member of the Johnson & Johnson JLABS network.

**Funds Raised:** \$20M in Seed funding at a \$50M valuation. Polymed is seeking Series A investors and partners.

---

## **POSTECH**

**Categorical Listings:** Biomanufacturing, Platform Technology, Vaccines

**Location:** Pohang,  
South Korea

**Established:** 1986

**Website:** postech.ac.kr/eng

**Presenter:** Seung Soo Oh, PhD,  
MS, Associate Professor

**Corporate Partners:** INP

**Funds Raised:** INP

## **Prazer Therapeutics**

**Categorical Listings:** CNS/Neurological, Oncology, Platform Technology

**Location:** Seoul,  
South Korea

**Established:** 2019

**Website:** prazertx.com

**Presenter:** Jungjin Ahn, MBA,  
Executive VP & CFO

**Corporate Partners:** The company is leveraging its TPD platform, SPiDEM™, to co-develop innovative therapies in collaboration with Daewon Pharma and Yuhan Corporation.

**Funds Raised:** \$13M in 2020. The current Series B round, positioned as a pre-IPO, is expected to secure over \$15M.

---

## **Premas Technologies Inc**

**Categorical Listings:** Infectious Disease, Vaccines, Veterinary

**Location:** Houston,  
Texas United States

**Established:** 2021

**Website:** premastechnologies.com

**Presenter:** Prabuddha (Kumar) Kundu,  
PhD, MSc, Director

**Corporate Partners:** INP

**Funds Raised:** Self funded: looking to raise \$5M.

---

## **PrimeLink Bio**

**Categorical Listings:** Antibodies, Oncology

**Location:** Suzhou Industrial Park,  
China

**Established:** 2021

**Website:** en.primelinkbio.com

**Presenter:** Mao Yin, PhD, CEO

**Corporate Partners:** The company is actively looking for partnering opportunities around its ADC modular technologies and pipeline products.

**Funds Raised:** INP

## **PRISM BioLab Co., Ltd.** (TSE:206A)

**Categorical Listings:** Drug Discovery, Platform Technology

**Location:** Fujisawa,  
Kanagawa Japan

**Established:** 2006

**Website:** prismbiolab.com

**Presenter:** Dai Takehara,  
MBA, President & CEO

**Corporate Partners:** Licensee: Eisai, Ohara  
Pharmaceuticals, Joint research: Eli Lilly, Roche, Genentech,  
Ono Pharma, Boehringer Ingelheim, Merck KGaA, Servier.

**Funds Raised:** More than \$60M funded including recent  
IPO raising \$14M at Tokyo Stock Exchange.

---

## **ProteoWise Inc.**

**Categorical Listings:** Platform Technology, Proteomics, Research Tools

**Location:** New Haven,  
Connecticut United States

**Established:** 2020

**Website:** proteowise.com

**Presenter:** Erik Gunther, PhD, CEO

**Corporate Partners:** Antibody content being developed in  
partnership with Cell Signaling Technology.

**Funds Raised:** \$25.5M so far. Raising \$15M Series B.

---

## **PURMX Therapeutics, Inc.**

**Categorical Listings:** DNA/RNA Synthesis, Drug Delivery, Oncology

**Location:** Hiroshima,  
Japan

**Established:** 2021

**Website:** purmx.com

**Presenter:** Kazuhiro (Kaz) Takahashi,  
PhD, CEO

**Corporate Partners:** INP

**Funds Raised:** \$8M Series A was completed by 2024.  
\$18M Series B is expected in 2025.

## **Radiopharm Theranostics (ASX:RAD)**

**Categorical Listings:** Oncology, Orphan/Rare Disease, Radiopharmaceuticals

**Location:** Carlton,  
Australia

**Corporate Partners:** Lantheus

**Funds Raised:** \$46M in 2021; \$43M in 2024.

**Established:** 2021

**Website:** radiopharmtheranostics.com

**Presenter:** Riccardo Canevari, CEO

## **Rakuten Medical, Inc.**

**Categorical Listings:** Antibodies, Oncology, Oncology Combination Therapy

**Location:** San Diego,  
California United States

**Corporate Partners:** Rakuten Medical has a number of strategic and research partners, including NIH, MD Anderson, and Merck KGaA. In 2023, Rakuten Medical and Hikma signed exclusive licensing agreement for MENA region.

**Established:** 2010

**Website:** rakuten-med.com

**Presenter:** Abhijit Bhatia,  
MS, MBA, COO

**Funds Raised:** \$822M in total. In Mar 2024, Rakuten Medical closed \$119M Series E financing to further develop its Alluminox™ platform.

## **Rege Nephro Co., Ltd.**

**Categorical Listings:** Cell Therapy, Regenerative Medicine, Renal

**Location:** Kyoto,  
Japan

**Corporate Partners:** Collaboration research with AstraZeneca on kidney assembloids, with Abu Dhabi Stem Cells Center on cell therapy for pancreas, and with Shimadzu, Nikkiso, and Mitsui Chemicals on cell therapy for kidneys.

**Established:** 2019

**Website:** regenephro.co.jp/en

**Presenter:** Akifumi Morinaka,  
PhD, MBA, CEO

**Funds Raised:** \$30M. Plan to raise \$40-50M Series C in 2025, triggered by POC for RN014.

## RejuvenRx Inc.

**Categorical Listings:** Epigenetics, Oncology, Regenerative Medicine

**Location:** Montreal,  
Quebec Canada

**Corporate Partners:** adMare Bioinnovations

**Established:** 2020

**Funds Raised:** \$750K as upfront payment in 2020 and 2 x \$500K as convertible debentures in 2022 and 2023.

**Website:** rejuvenrx.com

**Presenter:** Anne Marinier, PhD, CEO

---

## Remedy Plan Therapeutics

**Categorical Listings:** Autoimmune, Inflammation, Oncology

**Location:** Gaithersburg,  
Maryland United States

**Corporate Partners:** INP

**Established:** 2016

**Funds Raised:** \$37M to date and launching Series B round in Q4 2024.

**Website:** remedyplan.com

**Presenter:** Gregory Crimmins,  
PhD, CEO

---

## Repair Biotechnologies, Inc.

**Categorical Listings:** Cardiovascular, Gene Therapy, Orphan/Rare Disease

**Location:** Syracuse,  
New York United States

**Corporate Partners:** The company's LNP-mRNA therapy is developed in partnership with Genevant Sciences Corporation.

**Established:** 2018

**Website:** repairbiotechnologies.com

**Funds Raised:** More than \$19M in Seed round and SAFE note funding.

**Presenter:** Reason, MSc, CEO

## **RyboDyn, Inc.**

**Categorical Listings:** Antibodies, Drug Discovery, Immuno-oncology

**Location:** San Diego,  
California United States

**Established:** 2022

**Website:** rybodyn.com

**Presenter:** Imad Ajjawi,  
PhD, MBA, CEO

**Corporate Partners:** The company's novel therapeutic targets are being validated in partnership with Moffitt Cancer Center and the Knight Cancer Institute.

**Funds Raised:** \$3.95M in an oversubscribed pre-Seed round, closed November 2024.

---

## **Sarcomatrix Therapeutics Corp.**

**Categorical Listings:** Musculoskeletal, Orphan/Rare Disease, Regenerative Medicine

**Location:** Reno,  
Nevada United States

**Established:** 2022

**Website:** sarcomatrix.com

**Presenter:** David Robert Craig,  
MBA, Founder & CEO

**Corporate Partners:** Entrepreneur in Residence at University of Nevada Reno, Pending Resident Bayer Co.Lab Cambridge

**Funds Raised:** \$8M in NIH non-dilutive grants. \$300K to date, with \$2M soft circled.

---

## **Saros Therapeutics, Inc.**

**Categorical Listings:** Autoimmune, Drug Delivery, Immuno-oncology

**Location:** Chicago,  
Illinois United States

**Established:** 2022

**Website:** sarostx.com

**Presenter:** Jennifer Chadwick,  
PhD, CBO

**Corporate Partners:** INP

**Funds Raised:** INP



## **Sartorius** (Xetra:SRT)

**Categorical Listings:** Artificial Intelligence (AI), Biomanufacturing, Cell Therapy

**Location:** Göttingen,  
Germany

**Corporate Partners:** Public Company

**Established:** 1870

**Funds Raised:** Public Company

**Website:** sartorius.com

**Presenter:** René Faber, PhD, Head, BPS

---

## **SDK Therapeutics, Inc.**

**Categorical Listings:** Hematology, Oncology, Oncology Combination Therapy

**Location:** Mount Freedom,  
New Jersey United States

**Corporate Partners:** None

**Established:** 2024

**Funds Raised:** \$2.2M though SAFE and convertible notes in pre-Seed and Seed rounds.

**Website:** [www.linkedin.com/company/sdk-therapeutics](http://www.linkedin.com/company/sdk-therapeutics)

**Presenter:** Stephane Berthier, PharmD,  
MBA, MS, CEO

---

## **SFA Therapeutics, Inc.**

**Categorical Listings:** Autoimmune, Dermatology, Oncology

**Location:** Jenkintown,  
Pennsylvania United States

**Corporate Partners:** Under review by several strategic partners.

**Established:** 2016

**Funds Raised:** \$8.8M previously, \$50M raise underway to fund Phase 2/3 in psoriasis and to advance other assets into the clinic.

**Website:** [sfatherapeutics.com](http://sfatherapeutics.com)

**Presenter:** Ira C. Spector, PhD, CEO

## Shanghai Auzone Biotechnology Company

**Categorical Listings:** CNS/Neurological, Drug Discovery, Regenerative Medicine

**Location:** Shanghai, China

**Corporate Partners:** Huadong Pharmaceutical Company, China

**Established:** 2017

**Funds Raised:** \$20M before 2023, \$14M paid from the partner as the down payment in 2024.

**Website:** [szauzone.com](http://szauzone.com)

**Presenter:** Shangwei Hou, PhD, COO

## Shenzhen Kexing Pharmaceutical Co., Ltd.

**Categorical Listings:** Antibodies, Immunology, Immuno-oncology

**Location:** Shenzhen, China

**Corporate Partners:** The company does not have partners yet for majority of pipelines. The company cooperates with Southeast University (Nanjing, China) for exosome pipeline.

**Established:** 2018

**Funds Raised:** Not disclosed

**Website:** [synapse.patsnap.com/organization/b5a82cf0e3651b33773ee-256a986408f#profit](http://synapse.patsnap.com/organization/b5a82cf0e3651b33773ee-256a986408f#profit)

**Presenter:** Chenxi Guo, PhD, Licensing & BD Director

## Shenzhen Sungening Biological Co., Ltd

**Categorical Listings:** Infectious Disease, Microbiome

**Location:** Shenzhen, China

**Corporate Partners:** The company's invasive Aspergillus pipeline SG1001 is being developed in partnership with Livzon Groups in China region. Looking for partner and buyer in other country or districts.

**Established:** 2021

**Funds Raised:** First \$6M from 2022-2023. \$3M in 2024, with \$2M milestone payment in June 2024.

**Website:** [sungening.com](http://sungening.com)

**Presenter:** Yan Chen, MD, Chief Technology Officer

## **Skin2Neuron Pty Ltd**

**Categorical Listings:** Cell Therapy, CNS/Neurological, Platform Technology

**Location:** Sydney NSW,  
Australia

**Established:** 2019

**Website:** skin2neuron.org

**Presenter:** Brendon Boot, MD, CEO

**Corporate Partners:** The company has an SRA with the Jeff Schweitzer laboratory, Massachusetts General Hospital to co-develop its Parkinson Program. Dr. Schweitzer's team delivered the world's first autologous cell therapy for PD.

**Funds Raised:** Seed: \$1.5M, Series A 1st close: \$5M. Seeking additional tranches \$5M in Series A second close.

## **Spine BioPharma**

**Categorical Listings:** Biomanufacturing, Musculoskeletal, Neuropathy/Pain

**Location:** New York,  
New York United States

**Established:** 2015

**Website:** spinebiopharma.com

**Presenter:** Marc Viscogliosi, CEO

**Corporate Partners:** INP

**Funds Raised:** >\$50M

## **Starton Therapeutics**

**Categorical Listings:** Drug Delivery, Hematology, Platform Technology

**Location:** Paramus,  
New Jersey United States

**Established:** 2017

**Website:** startontx.com

**Presenter:** Pedro Lichtinger, MBA,  
Chairman & CEO

**Corporate Partners:** INP

**Funds Raised:** Approximately \$50M since being founded in 2017.

## **Stem Cell & Device Laboratory, Inc.**

**Categorical Listings:** Cell Therapy, Neurology, Regenerative Medicine

**Location:** Kyoto,  
Japan

**Established:** 2014

**Website:** scad-kyoto.com

**Presenter:** Kensuke Kato,  
PhD, CEO

**Corporate Partners:** The company is looking for partners.

**Funds Raised:** \$10M and \$3M in government grants to date.

---

## **STIMIT AG**

**Categorical Listings:** Other

**Location:** Biel-Bienne,  
Switzerland

**Established:** 2018

**Website:** stimit.com

**Presenter:** Ronja Bruhn, MBA, CEO

**Corporate Partners:** Main partners are neurocare group from Germany, Technology Integration from Romania, and Drägerwerk from Germany.

**Funds Raised:** More than \$20M to date.

---

## **Synthis Therapeutics, Inc.**

**Categorical Listings:** Fibrosis, Immunology, Pulmonary

**Location:** New York,  
New York United States

**Established:** 2018

**Website:** synthistx.com

**Presenter:** Dori Ann Thomas-Karyat,  
PhD, CEO & Founder

**Corporate Partners:** The company is currently looking for corporate partners.

**Funds Raised:** INP

## Teclison Corporation

**Categorical Listings:** Immuno-oncology, Oncology, Oncology Combination Therapy

**Location:** Princeton,  
New Jersey United States

**Established:** 2014

**Website:** [teclison.com](http://teclison.com)

**Presenter:** Ray Lee, MD, PhD, CEO

**Corporate Partners:** In partnership with Merck (MSD) using Pembrolizumab for immunotherapy-refractory colorectal and lung cancer study.

**Funds Raised:** Totally \$30M since 2014, plus \$6M out-licensing fee from China. Last round \$15M Oct. 2023.

## Tiba Biotech, LLC

**Categorical Listings:** Gene Therapy, Inflammation, Oncology

**Location:** Cambridge,  
Massachusetts United States

**Established:** 2018

**Website:** [tiba.bio](http://tiba.bio)

**Presenter:** Jasdave Chahal, PhD,  
Co-Founder & Lead Scientist

**Corporate Partners:** None currently, working toward product development partnerships in 2025.

**Funds Raised:** \$4M with \$10M in non-dilutive grants to 12/2024, and future contractually committed revenue of \$5M.

## TiCARos, Co.

**Categorical Listings:** Cell Therapy, Gene Therapy, Platform Technology

**Location:** Seoul,  
South Korea

**Established:** 2018

**Website:** [ticaros.com/en](http://ticaros.com/en)

**Presenter:** Daniel Suhong Kim, Director

**Corporate Partners:** The company is co-developing CLIP-CAR-iNK with AU company Cartherics, and they are also co-developing GBM targeting CAR-T with City of Hope.

**Funds Raised:** \$28M investments, \$8M research funding. Total of \$36M

## **TikkunLev Therapeutics**

**Categorical Listings:** Cardiovascular, Gene Therapy

**Location:** Tampa,  
Florida United States

**Corporate Partners:** INP

**Established:** 2022

**Funds Raised:** INP

**Website:** tikkunlev.com

**Presenter:** Matt Killeen, PhD, President

---

## **Tikva Allocell Pte Ltd**

**Categorical Listings:** Autoimmune, Cell Therapy, Oncology

**Location:** Singapore

**Corporate Partners:** Pipeline is developed in collaboration with A\*STAR, IMCB and Baylor College of Medicine (BCM).

**Established:** 2023

**Website:** tikvaallocell.com

**Funds Raised:** INP

**Presenter:** Ivan David Horak,  
MD, Founder & CEO

---

## **Tiziana Life Sciences (NASDAQ:TLSA)**

**Categorical Listings:** Antibodies, CNS/Neurological, Inflammation

**Location:** London,  
United Kingdom

**Corporate Partners:** None currently.

**Established:** 2013

**Funds Raised:** \$57M in 2020, various non-dilutive funding received in 2024.

**Website:** tizianalifesciences.com

**Presenter:** Ivor Elrifi, PhD, CEO

---

---

## **Tonix Pharmaceuticals** (NASDAQ:TNXP)

**Categorical Listings:** CNS/Neurological, Immunology, Infectious Disease

**Location:** Chatham,  
New Jersey United States

**Corporate Partners:** INP

**Established:** 2013

**Funds Raised:** INP

**Website:** tonixpharma.com

**Presenter:** Seth Lederman,  
MD, Co-Founder, CEO & Chairman

---

## **Trellis Bioscience, Inc.**

**Categorical Listings:** Antibodies, Infectious Disease, Orphan/Rare Disease

**Location:** Redwood City,  
California United States

**Corporate Partners:** None

**Established:** 2010

**Funds Raised:** More than \$25M in equity and \$36M in non-dilutive funding.

**Website:** trellisbio.com

**Presenter:** Stefan Ryser, PhD, CEO

---

## **Treos Bio**

**Categorical Listings:** Big Data, Immuno-oncology, Oncology

**Location:** London,  
United Kingdom

**Corporate Partners:** Mayo Clinic, Roche, Charite Berlin,  
Junshi Biosciences

**Established:** 2017

**Funds Raised:** \$60M to date, o/w \$45M equity and \$15M grant/in-kind support.

**Website:** treosbio.com

**Presenter:** Christopher Gallen,  
MD, PhD, CEO

## Triplebar Bio Inc.

**Categorical Listings:** Artificial Intelligence (AI), Personalized Medicine, Research Tools

**Location:** Emeryville,  
California United States

**Corporate Partners:** Undisclosed

**Funds Raised:** \$26M to date.

**Established:** 2019

**Website:** triplebar.com

**Presenter:** Maria Cho, MS, CEO

---

## Ubix Therapeutics, Inc.

**Categorical Listings:** Drug Discovery, Oncology, Platform Technology

**Location:** Seoul,  
South Korea

**Corporate Partners:** The company's Androgen Receptor degrader pipeline is being developed in partnership with Yuhan.

**Established:** 2018

**Website:** ubixtrx.com

**Funds Raised:** The total accumulated investment up to the pre-IPO stage is ₩60B.

**Presenter:** Hyunjin Yang, PhD,  
Director, Business Development

---

## VerImmune Inc

**Categorical Listings:** Drug Delivery, Immuno-oncology, Platform Technology

**Location:** Singapore

**Corporate Partners:** J&J, A\*STAR, Protect Animal Health

**Established:** 2019

**Funds Raised:** INP

**Website:** verimmune.com

**Presenter:** Joshua Wang,  
Founder & CEO

---



## **Viking Scientific, Inc.**

**Categorical Listings:** Drug Delivery, Musculoskeletal, Orphan/Rare Disease

**Location:** San Marcos,  
California United States

**Corporate Partners:** None

**Established:** 2022

**Funds Raised:** Approximately \$750K to date, inclusive of parent company (Viking Scientific, Inc.).

**Website:** vikingscientificinc.com

**Presenter:** Paul Fisher, PhD, CEO

---

## **VSP PharmTech**

**Categorical Listings:** Oncology, Oncology Combination Therapy, Radiopharmaceuticals

**Location:** Seoul,  
South Korea

**Corporate Partners:** Advanced in research collaboration with a radiopharmaceutical company. Actively seeking partnership for global licensing of VS-101.

**Established:** 2018

**Funds Raised:** \$13M in total including \$8M of Series B round in 2023.

**Website:** vspharmtech.com

**Presenter:** Hoyun Nam, Director

---

## **Wayshine Biopharm Inc**

**Categorical Listings:** Oncology, Orphan/Rare Disease, Personalized Medicine

**Location:** Corona,  
California United States

**Corporate Partners:** The company's oncology pipeline of CNS penetrable target therapy is being developed in partnership with big pharma and top research institutions in U.S. and China.

**Established:** 2016

**Funds Raised:** More than \$25M from Angel and Series A to date.

**Website:** wayshinebiopharm.com

**Presenter:** Wei Zhong, PhD, CEO

## Westlake Genetech

**Categorical Listings:** Artificial Intelligence (AI), Drug Delivery, Gene Therapy

**Location:** Hangzhou, China

**Established:** 2021

**Website:** [www.westlakegenetech.com/en/index.html](http://www.westlakegenetech.com/en/index.html)

**Presenter:** Lijia Ma, PhD, Scientific Founder

**Corporate Partners:** Westlake Genetech is actively seeking business development opportunities to license its neurotropic and muscle-tropic AAV variants, as well as its clinical-stage ex vivo CRISPR pipeline.

**Funds Raised:** \$1.5M in the past two rounds.

## Wuhan ZYZ Biopharma Co., Ltd. (HKEX:2496)

**Categorical Listings:** Antibodies, Immuno-oncology, Platform Technology

**Location:** Wuhan, China

**Established:** 2010

**Website:** [zyzbio.com](http://zyzbio.com)

**Presenter:** Pengfei Zhou, PhD, MS, CEO

**Corporate Partners:** The company's ophthalmology pipeline, Y400(VEGFxANG2), is being developed in partnership with Shenzhen Kangzhe Vision Pharmaceutical Development Co., Ltd, a wholly-owned subsidiary of China Medical System Holdings Limited (0867.HK.).

**Funds Raised:** ¥950M (~\$135M) in financing rounds and IPO.

## Xylyx Bio, Inc.

**Categorical Listings:** Platform Technology, Regenerative Medicine, Transplant

**Location:** Brooklyn, New York United States

**Established:** 2016

**Website:** [xylyxbio.com](http://xylyxbio.com)

**Presenter:** Andrea Nye, MBA, MPH, CEO

**Corporate Partners:** Active discussions with multiple prospective industry partners.

**Funds Raised:** INP

## **ZTI Biosciences Co., Ltd.**

**Categorical Listings:** Oncology, Platform Technology, Radiopharmaceuticals

**Location:** Zionsville,  
Indiana United States

**Corporate Partners:** None

**Established:** 2020

**Funds Raised:** \$1.5M in grants and \$10.5M in Pre-A funding, totaling \$12M since 2020.

**Website:** zti-bio.com

**Presenter:** Jaden Hyungseok Chang,  
PhD, MEng, CEO

---

## **ZYUS Life Sciences Corporation (TSX:ZYUS)**

**Categorical Listings:** Inflammation, Neuropathy/Pain, Other

**Location:** Saskatoon,  
Saskatchewan Canada

**Corporate Partners:** No corporate partners

**Established:** 2016

**Funds Raised:** More than CAD \$100M since inception, including CAD ~\$20M on initial listing (June 2023 RTO).

**Website:** zyus.com

**Presenter:** John Hyshka, CFO



2025

# BIOTECH SHOWCASE™

Categorical Listings



## Antibodies

Axcynsis Therapeutics

Bectas Therapeutics Inc.

Beech Biotech SA

Beijing CorreGene Biotechnology Co., Ltd

Biomissile Pharmaceuticals

Cellergy Pharma Inc.

Guangdong Fapon Biopharma Inc.

Huonslab Co. Ltd.,

iBio, Inc.

iBody Inc.

Ichnos Glenmark Innovation (IGI)

IMBiologics

MOLCURE Inc.

OCMS Bio LLC

Ordaōs

PairX Bio

PrimeLink Bio

Rakuten Medical, Inc.

RyboDyn, Inc.

Shenzhen Kexing Pharmaceutical Co., Ltd.

Tiziana Life Sciences

Trellis Bioscience, Inc.

Wuhan YZY Biopharma Co., Ltd.

## Artificial Intelligence (AI)

Atom Bioworks

Gain Therapeutics, Inc.

Ignota Labs

InfiniTopes Precision Immunomics

MOLCURE Inc.

MultiOmic Health Limited

Novigenix SA

Nutshell Therapeutics

Ordaōs

Owl Therapeutics

Sartorius

Triplebar Bio Inc.

Westlake Genetech

## Autoimmune

Abacus Bioscience Inc

Accropeutics

Alpina Biotechnology, Inc.

Ananda Immunotherapies SG Pte Ltd

Aqilion AB

Biomissile Pharmaceuticals

Coval Biopharma Co., Ltd.

Enhanc3D Genomics Ltd

Guangdong Fapon Biopharma Inc.

Ichnos Glenmark Innovation (IGI)

**Autoimmune (Cont'd)**

Phecda Medicine Co., Ltd.

---

Remedy Plan Therapeutics

---

Saros Therapeutics, Inc.

---

SFA Therapeutics, Inc.

---

Tikva Allocell Pte Ltd

---

**Big Data**

Enhanc3D Genomics Ltd

---

Treos Bio

---

**Bioinformatics**

Ignota Labs

---

PairX Bio

---

**Biomufacturing**

Cellevate AB

---

CryoStasis Inc

---

Ori Biotech

---

POSTECH

---

Sartorius

---

Spine BioPharma

---

**Cardiovascular**

Affinia Therapeutics

---

Cereno Scientific AB

---

Cigma

---

Genvara Biopharma, Inc.

---

**Cardiovascular (Cont'd)**

Help Therapeutics Co. Ltd.

---

Mesoblast Limited

---

Microvascular Therapeutics, Inc

---

MitrAssist Lifesciences Limited

---

Repair Biotechnologies, Inc.

---

TikkunLev Therapeutics

---

**Cell Therapy**

AdAlta Limited

---

Akadeum Life Sciences, Inc.

---

Atom Bioworks

---

Avobis Bio

---

Beijing CorreGene Biotechnology Co., Ltd

---

Cellergy Pharma Inc.

---

CelluGenix Biotech Inc.

---

Chimeric Therapeutics

---

CryoStasis Inc

---

Cynata Therapeutics Pty Ltd.

---

ExCellThera Inc.

---

FibroBiologics

---

Help Therapeutics Co. Ltd.

---

IN8bio, Inc

---

Lipo-Immuno Tech, LLC

---

Longeveron Inc.

---

Mesoblast Limited

---

MKC Biotherapeutics, Inc.

---

**Cell Therapy (Cont'd)**

---

Ori Biotech

---

Pan Cancer T B.V.

---

Rege Nephro Co., Ltd.

---

Sartorius

---

Skin2Neuron Pty Ltd

---

Stem Cell & Device Laboratory, Inc.

---

TiCARos, Co.

---

Tikva Allocell Pte Ltd

---

**CNS/Neurological**

---

4B Technologies, Ltd

---

Aelis Farma

---

Affinia Therapeutics

---

Alyea Therapeutics (Subsidiary of  
Alt 5 Sigma)

---

Artery Therapeutics, Inc.

---

Bexion Pharmaceuticals, Inc.

---

BioStrategies LC

---

CELLeBRAIN

---

Gain Therapeutics, Inc.

---

Hyundai Bioscience Co. Ltd.

---

Microvascular Therapeutics, Inc

---

MindImmune Therapeutics Inc.

---

NeuExcell Therapeutics Inc

---

NuvOx Therapeutics

---

Origenis GmbH

---

Owl Therapeutics

---

**CNS/Neurological (Cont'd)**

---

Phecda Medicine Co., Ltd.

---

Prazer Therapeutics

---

Shanghai Auzone Biotechnology  
Company

---

Skin2Neuron Pty Ltd

---

Tiziana Life Sciences

---

Tonix Pharmaceuticals

---

**Contract Manufacturing**

---

BioStem Technologies, Inc.

---

**CRISPR**

---

GenAssist Ltd

---

**Dermatology**

---

Aelis Farma

---

Alphyn Biologics

---

Azitra Inc.

---

JW Pharmaceutical Corporation

---

Livionex Inc.

---

SFA Therapeutics, Inc.

---

**Diagnostics**

---

Dx&Vx Co., Ltd

---

GeneCapture, Inc.

---

Livivos Inc

---

MitrAssist Lifesciences Limited

---



**Diagnostics (Cont'd)**

Nanopath

---

Path Fertility (FKA: Inherent  
Biosciences)

---

**DNA/RNA Synthesis**

PURMX Therapeutics, Inc.

---

**Drug Delivery**

Atom Bioworks

---

GelMEDIX, Inc.

---

GenAssist Ltd

---

IVIEW Therapeutics Inc.

---

PDX Pharmaceuticals, Inc.

---

PURMX Therapeutics, Inc.

---

Saros Therapeutics, Inc.

---

Starton Therapeutics

---

VerImmune Inc

---

Viking Scientific, Inc.

---

Westlake Genetech

---

**Drug Discovery**

Alveolus Bio

---

Angiex, Inc.

---

Biomia

---

Empath Biosciences

---

Gain Therapeutics, Inc.

---

**Drug Discovery (Cont'd)**

Gluetacs Therapeutics (Shanghai)  
Co., Ltd.

---

iBio, Inc.

---

iBody Inc.

---

Immuto Scientific

---

Lahjavid, Inc.

---

LoxiGen, Inc.

---

MindImmune Therapeutics Inc.

---

MultiOmic Health Limited

---

Nalu Bio

---

Nutshell Therapeutics

---

OCMS Bio LLC

---

Ordaos

---

Origenis GmbH

---

Perspective Therapeutics, Inc.

---

PRISM BioLab Co., Ltd.

---

RyboDyn, Inc.

---

Shanghai Auzone Biotechnology  
Company

---

Ubix Therapeutics, Inc.

---

**Endocrine/Metabolic**

Aelis Farma

---

AUM Biosciences

---

Eleva GmbH

---

Ignota Labs

---

JW Pharmaceutical Corporation

---

**Endocrine/Metabolic  
(Cont'd)**

MitoRx Therapeutics Limited

MultiOmic Health Limited

Perseo pharma AG

PG Pharma

**Epigenetics**

Cereno Scientific AB

Path Fertility (FKA: Inherent Biosciences)

RejuvenRx Inc.

**Fibrosis**

AdAlta Limited

Cynata Therapeutics Pty Ltd.

Livivos Inc

Lmito Therapeutics Inc.

LoxiGen, Inc.

Synthis Therapeutics, Inc.

**Gastrointestinal**

Accropeutics

Aqilion AB

Avobis Bio

Jaguar Health, Inc.

Livivos Inc

LPOXY Therapeutics, Inc

Perseo pharma AG

**Gene Therapy**

Affinia Therapeutics

Akadeum Life Sciences, Inc.

CELLeBRAIN

Cellevate AB

CelluGenix Biotech Inc.

IVIEW Therapeutics Inc.

Kanglin Biotec (Hangzhou) Co., Ltd.

Kinea Bio, Inc.

NeuExcell Therapeutics Inc

Ori Biotech

Repair Biotechnologies, Inc.

Tiba Biotech, LLC

TiCARos, Co.

TikkunLev Therapeutics

Westlake Genetech

**Hematology**

BioNova Pharmaceuticals Ltd.

Chimeric Therapeutics

Coagulant Therapeutics

IASO Biotechnology

Kanglin Biotec (Hangzhou) Co., Ltd.

Mogling Bio Inc

SDK Therapeutics, Inc.

Starton Therapeutics

**Immunology**

---

Accropeutics

---

Aegle Therapeutics Corporation

---

Alphyn Biologics

---

Alpina Biotechnology, Inc.

---

Ananda Immunotherapies SG Pte  
Ltd

---

Bectas Therapeutics Inc.

---

Changchun GeneScience  
Pharmaceutical Co., Ltd. (GenSci)

---

Cynata Therapeutics Pty Ltd.

---

Eleva GmbH

---

Gluetacs Therapeutics (Shanghai)  
Co., Ltd.

---

IASO Biotechnology

---

Lmito Therapeutics Inc.

---

Pilatus Biosciences

---

Polymed Biopharmaceuticals, Inc.

---

Shenzhen Kexing Pharmaceutical  
Co., Ltd.

---

Synthis Therapeutics, Inc.

---

Tonix Pharmaceuticals

**Immuno-oncology**

---

Abacus Bioscience Inc

---

AIVITA Biomedical, Inc.

---

Akadeum Life Sciences, Inc.

---

Biomissile Pharmaceuticals

---

Cellergy Pharma Inc.

**Immuno-oncology (Cont'd)**

---

Dx&Vx Co., Ltd

---

GeoVax Labs, Inc.

---

Guangdong Fapon Biopharma  
Inc.

---

Hemay Pharmaceuticals

---

Ichnos Glenmark Innovation (IGI)

---

IMBiologics

---

IN8bio, Inc

---

Infinitopes Precision Immunomics

---

IO Biotech, Inc.

---

Mogling Bio Inc

---

Multimeric Biotherapeutics, Inc.

---

Nammi Therapeutics, Inc.

---

Novigenix SA

---

Oncolytics Biotech INC.

---

PairX Bio

---

Pan Cancer T B.V.

---

PDX Pharmaceuticals, Inc.

---

RyboDyn, Inc.

---

Saros Therapeutics, Inc.

---

Shenzhen Kexing Pharmaceutical  
Co., Ltd.

---

Teclison Corporation

---

Treos Bio

---

VerImmune Inc

---

Wuhan YZY Biopharma Co., Ltd.

**Infectious Disease**

---

AstriVax

---

Coagulant Therapeutics

---

GeneCapture, Inc.

---

GeoVax Labs, Inc.

---

Hyundai Bioscience Co. Ltd.

---

LPOXY Therapeutics, Inc

---

Multimeric Biotherapeutics, Inc.

---

Mustbio Co., Ltd.

---

Nanopath

---

NanoViricides, Inc.

---

OCMS Bio LLC

---

Premas Technologies Inc

---

Shenzhen Sungening Biological Co., Ltd

---

Tonix Pharmaceuticals

---

Trellis Bioscience, Inc.

---

**Inflammation**

---

Abacus Bioscience Inc

---

Aegle Therapeutics Corporation

---

Alpina Biotechnology, Inc.

---

Alveolus Bio

---

Aqilion AB

---

Chrysalis BioTherapeutics, Inc.

---

Coval Biopharma Co., Ltd.

---

Hemay Pharmaceuticals

---

Livionex Inc.

---

Mesoblast Limited

---

**Inflammation (Cont'd)**

---

MindImmune Therapeutics Inc.

---

Nalu Bio

---

PG Pharma

---

Polymed Biopharmaceuticals, Inc.

---

Remedy Plan Therapeutics

---

Tiba Biotech, LLC

---

Tiziana Life Sciences

---

ZYUS Life Sciences Corporation

---

**Longevity/Healthspan/  
Diseases of Aging**

---

Artery Therapeutics, Inc.

---

FibroBiologics

---

Immunis, Inc.

---

Longeveron Inc.

---

**Longevity/Healthspan/  
Diseases of Aging (Cont'd)**

---

MKC Biotherapeutics, Inc.

---

Mogling Bio Inc

---

**Machine Learning**

---

Empath Biosciences

---

iBio, Inc.

---

iBody Inc.

---

**Microbiome**

Alphyn Biologics

---

Azitra Inc.

---

Shenzhen Sungening Biological  
Co., Ltd

---

**Mitochondrial  
Therapeutic**

Empath Biosciences

---

Huonslab Co. Ltd.,

---

Lipo-Immuno Tech, LLC

---

MitoRx Therapeutics Limited

---

Owl Therapeutics

---

Phecda Medicine Co., Ltd.

---

**Musculoskeletal**

Alyea Therapeutics (Subsidiary of  
Alt 5 Sigma)

---

Immunis, Inc.

---

Kinea Bio, Inc.

---

MitoRx Therapeutics Limited

---

Sarcomatrix Therapeutics Corp.

---

Spine BioPharma

---

Viking Scientific, Inc.

---

**Neurology**

4B Technologies, Ltd

---

IASO Biotechnology

---

Stem Cell & Device Laboratory, Inc.

---

**Neuropathy/Pain**

4B Technologies, Ltd

---

Alyea Therapeutics (Subsidiary of  
Alt 5 Sigma)

---

Artery Therapeutics, Inc.

---

Bexion Pharmaceuticals, Inc.

---

Biomia

---

Nalu Bio

---

Osmol Therapeutics, Inc.

---

PG Pharma

---

Spine BioPharma

---

ZYUS Life Sciences Corporation

---

**Oncology**

Angiex, Inc.

---

AUM Biosciences

---

Aurigene Oncology Limited

---

Avistone Biotechnology

---

Axcynsis Therapeutics

---

Bectas Therapeutics Inc.

---

Beijing CorreGene Biotechnology  
Co., Ltd

---

Bexion Pharmaceuticals, Inc.

---

BioNova Pharmaceuticals Ltd.

---

CELLeBRAIN

---

Collectar Biosciences Inc.

---

Changchun GeneScience  
Pharmaceutical Co., Ltd. (GenSci)

---

Chimeric Therapeutics

---

**Oncology (Cont'd)**

CNCure Co., Ltd.

ExCellThera Inc.

GeneTether Therapeutics Inc.

Gluetacs Therapeutics (Shanghai)  
Co., Ltd.

Hemay Pharmaceuticals

Immuto Scientific

IN8bio, Inc

Jaguar Health, Inc.

JW Pharmaceutical Corporation

Lahjavidia, Inc.

Lipo-Immuno Tech, LLC

LoxiGen, Inc.

MAIA Biotechnology, Inc.

MEKanistic Therapeutics, Inc.

Microvascular Therapeutics, Inc

Mustbio Co., Ltd.

NuvOx Therapeutics

Oncolytics Biotech INC.

Osmol Therapeutics, Inc.

Pan Cancer T B.V.

Perspective Therapeutics, Inc.

Pilatus Biosciences

Polymed Biopharmaceuticals, Inc.

Prazer Therapeutics

PrimeLink Bio

PURMX Therapeutics, Inc.

**Oncology (Cont'd)**

Radiopharm Theranostics

Rakuten Medical, Inc.

RejuvenRx Inc.

Remedy Plan Therapeutics

SDK Therapeutics, Inc.

SFA Therapeutics, Inc.

Tiba Biotech, LLC

Tikva Allocell Pte Ltd

Treos Bio

Ubix Therapeutics, Inc.

VSP PharmTech

Wayshine Biopharm Inc

ZTI Biosciences Co., Ltd.

**Oncology Combination  
Therapy**

AUM Biosciences

BioNova Pharmaceuticals Ltd.

Cellectar Biosciences Inc.

CNCure Co., Ltd.

Hyundai Bioscience Co. Ltd.

MAIA Biotechnology, Inc.

Nammi Therapeutics, Inc.

Origenis GmbH

Rakuten Medical, Inc.

SDK Therapeutics, Inc.

**Oncology Combination  
Therapy (Cont'd)**

---

Teclison Corporation

---

VSPHarmTech

---

**Ophthalmic**

---

Epion Therapeutics, Inc.

---

GelMEDIX, Inc.

---

IVIEW Therapeutics Inc.

---

Livionex Inc.

---

Mobius Scientific, Inc.

---

**Orphan/Rare Disease**

---

AdAlta Limited

---

Aegle Therapeutics Corporation

---

Azitra Inc.

---

BioStrategies LC

---

Cereno Scientific AB

---

Coagulant Therapeutics

---

GenAssist Ltd

---

Jaguar Health, Inc.

---

Kanglin Biotec (Hangzhou) Co.,  
Ltd.

---

Kinea Bio, Inc.

---

Lmito Therapeutics Inc.

---

Mobius Scientific, Inc.

---

NanoViricides, Inc.

---

Perseo pharma AG

---

**Orphan/Rare Disease**

---

Radiopharm Theranostics

---

Repair Biotechnologies, Inc.

---

Sarcomatrix Therapeutics Corp.

---

Trellis Bioscience, Inc.

---

Viking Scientific, Inc.

---

Wayshine Biopharm Inc

---

**Other**

---

Cigma

---

Galena Innovations, Inc.

---

InkSpace Imaging, Inc.

---

STIMIT AG

---

ZYUS Life Sciences Corporation

---

**Personalized Medicine**

---

AIVITA Biomedical, Inc.

---

Cigma

---

Genvara Biopharma, Inc.

---

Infinitopes Precision Immunomics

---

Triplebar Bio Inc.

---

Wayshine Biopharm Inc

---

**Pharmacogenetics**

---

Genvara Biopharma, Inc.

---

**Platform Technology**

Angiex, Inc.

---

AstriVax

---

Axcynsis Therapeutics

---

BioStrategies LC

---

CelluGenix Biotech Inc.

---

Coval Biopharma Co., Ltd.

---

Eleva GmbH

---

Enhanc3D Genomics Ltd

---

ExCellThera Inc.

---

GeneCapture, Inc.

---

IMBiologics

---

Immuto Scientific

---

InkSpace Imaging, Inc.

---

Lahjavidia, Inc.

---

Mobius Scientific, Inc.

---

MOLCURE Inc.

---

Nammi Therapeutics, Inc.

---

Novigenix SA

---

Nutshell Therapeutics

---

NuvOx Therapeutics

---

PDX Pharmaceuticals, Inc.

---

POSTECH

---

Prazer Therapeutics

---

PRISM BioLab Co., Ltd.

---

ProteoWise Inc.

---

Skin2Neuron Pty Ltd

---

Starton Therapeutics

---

**Platform Technology (Cont'd)**

TiCARos, Co.

---

Ubix Therapeutics, Inc.

---

VerImmune Inc

---

Wuhan YZY Biopharma Co., Ltd.

---

Xylyx Bio, Inc.

---

ZTI Biosciences Co., Ltd.

---

**Proteomics**

ProteoWise Inc.

---

**Psychiatric**

Biomia

---

**Pulmonary**

Alveolus Bio

---

Chrysalis BioTherapeutics, Inc.

---

NanoViricides, Inc.

---

Synthis Therapeutics, Inc.

---

**Radiopharmaceuticals**

Cellectar Biosciences Inc.

---

CNCure Co., Ltd.

---

Perspective Therapeutics, Inc.

---

Radiopharm Theranostics

---

VSPHarmTech

---

ZTI Biosciences Co., Ltd.

---



**Regenerative Medicine**

Avobis Bio

---

BioStem Technologies, Inc.

---

Chrysalis BioTherapeutics, Inc.

---

FibroBiologics

---

GelMEDIX, Inc.

---

Help Therapeutics Co. Ltd.

---

Immunis, Inc.

---

Longeveron Inc.

---

MKC Biotherapeutics, Inc.

---

NeuExcell Therapeutics Inc

---

Rege Nephro Co., Ltd.

---

RejuvenRx Inc.

---

Sarcomatrix Therapeutics Corp.

---

Shanghai Auzone Biotechnology  
Company

---

Stem Cell & Device Laboratory, Inc.

---

Xylyx Bio, Inc.

---

**Renal**

Rege Nephro Co., Ltd.

---

**Reproductive Medicine**

Galena Innovations, Inc.

---

Path Fertility

(FKA: Inherent Biosciences)

---

**Research Tools**

ProteoWise Inc.

---

Triplebar Bio Inc.

---

**Transplant**

Xylyx Bio, Inc.

---

**Vaccines**

AIVITA Biomedical, Inc.

---

AstriVax

---

Cellevate AB

---

Dx&Vx Co., Ltd

---

GeoVax Labs, Inc.

---

Multimeric Biotherapeutics, Inc.

---

POSTECH

---

Premas Technologies Inc

---

**Veterinary**

Premas Technologies Inc

---

**Women's Health**

Beech Biotech SA

---

Changchun GeneScience  
Pharmaceutical Co., Ltd. (GenSci)

---

Galena Innovations, Inc.

---

Nanopath

---

2025

# TECHBIO SHOWCASE



Presenting Company  
Profiles



## **Adva Biotechnology Ltd**

**Categorical Listings:** Cell Therapy, Gene Therapy, Regenerative Medicine

**Location:** BarLev Hightech Park,  
Israel

**Corporate Partners:** INP

**Funds Raised:** \$22M

**Established:** 2017

**Website:** advabio.com

**Presenter:** Ohad Karnieli,  
PhD, MBA, Founder & CEO

---

## **AI Proteins**

**Categorical Listings:** Artificial Intelligence (AI), Platform Technology, Radiopharmaceuticals

**Location:** Boston,  
Massachusetts United States

**Corporate Partners:** Multiple major pharma partners  
including BMS (others can be shared under NDA).

**Established:** 2021

**Funds Raised:** \$30M in VC money to date, with additional  
non-dilutive pharma funding that can be shared under  
NDA.

**Website:** aiproteins.bio

**Presenter:** Chris Bahl,  
PhD, MS, CSO, Founder

---

## **Aikium Inc.**

**Categorical Listings:** Artificial Intelligence (AI), Oncology, Platform Technology

**Location:** Oakland,  
California United States

**Corporate Partners:** One licensing deal is about to be  
closed, but cannot share further now.

**Established:** 2022

**Funds Raised:** \$2.5M in pre-Seed; applied for SBIR Phase I;  
big pharma partnership about to be closed.

**Website:** aikium.com

**Presenter:** Eswar Iyer, PhD, CEO

## **Atombeat, a DP Technology Company**

**Categorical Listings:** Artificial Intelligence (AI), Drug Discovery, Platform Technology

**Location:** Jersey City,  
New Jersey United States

**Established:** 2018

**Website:** atombeat.com

**Presenter:** Liyu Wu,  
PhD, MBA, Head, Commercial

**Corporate Partners:** An antibody drug conjugate pipeline is being developed in collaboration with Lepu Biopharma Co., Ltd.

**Funds Raised:** More than \$200M since 2018.

---

## **Avecris Pte. Ltd.**

**Categorical Listings:** Gene Therapy, Platform Technology

**Location:** Singapore

**Established:** 2022

**Website:** avecris.com

**Presenter:** Dennis Mak, MBA,  
Co-Founder

**Corporate Partners:** Not publicly disclosed

**Funds Raised:** INP

---

## **Avectas**

**Categorical Listings:** Autoimmune, Cell Therapy, Immuno-oncology

**Location:** Dublin,  
Ireland

**Established:** 2012

**Website:** avectas.com

**Presenter:** Michael Maguire,  
PhD, CEO

**Corporate Partners:** Undisclosed

**Funds Raised:** More than \$65M to date.

## BrainScope

**Categorical Listings:** Bioinformatics, CNS/Neurological, Drug Discovery

**Location:** Rockville,  
Maryland United States

**Established:** 2006

**Website:** brainscope.com

**Presenter:** Laurie Silver, CEO

**Corporate Partners:** No corporate partners to date. ADDF (Alzheimer's Drug Discovery Foundation) recently invested to fund development of a successful proof-of-concept biomarker for earliest prediction of Alzheimer's.

**Funds Raised:** More than \$100M including \$30M in non-dilutive funding from the DoD, NFL, GE and ADDF.

## BrilliantStrings Therapeutics

**Categorical Listings:** CRISPR, Musculoskeletal, Regenerative Medicine

**Location:** Lincoln,  
Massachusetts United States

**Established:** 2021

**Website:** brilliantstringsthx.com

**Presenter:** Jeffrey Ruberti,  
PhD, CEO

**Corporate Partners:** None

**Funds Raised:** More than \$2.4M in 2024, \$110K in non-dilutive awards and \$2.3M in a convertible note.

## CellFE Inc.

**Categorical Listings:** Biomanufacturing, Cell Therapy, Immuno-oncology

**Location:** Alameda,  
California United States

**Established:** 2019

**Website:** cellfebiotech.com

**Presenter:** Alla Zamarayeva,  
PhD, CEO

**Corporate Partners:** Ten partners including three large pharma, translational centers and biotech.

**Funds Raised:** \$40M

## Enquyst Technologies Inc

**Categorical Listings:** Biomanufacturing, Platform Technology, Research Tools

**Location:** Lowell,  
Massachusetts United States

**Established:** 2017

**Website:** [enquyst.com](http://enquyst.com)

**Presenter:** Jason Criscione,  
PhD, Founder & CSO

**Corporate Partners:** Enquyst is collaborating with CDMOs, equipment suppliers, and pharma companies to evaluate its IPP technology.

**Funds Raised:** \$10M to date.

---

## Exogene Limited

**Categorical Listings:** Antibodies, Artificial Intelligence (AI), Immuno-oncology

**Location:** Oxford,  
United Kingdom

**Established:** 2020

**Website:** [exogene.co.uk](http://exogene.co.uk)

**Presenter:** Federico Paoletti,  
PhD, CEO & Co-Founder

**Corporate Partners:** Exogene has paid collaborations with top TCR players: Immunocore (developer of the first FDA-approved TCR-based BiTE) and Enara Bio.

**Funds Raised:** \$5.5M to date, \$2.1M from VC, \$3.4M in non-dilutive funding.

---

## Fermelanta, Inc.

**Categorical Listings:** Biomanufacturing, Generics, Platform Technology

**Location:** Ishikawa-ken,  
Nonoichi Japan

**Established:** 2022

**Website:** [fermelanta.com](http://fermelanta.com)

**Presenter:** Lucas Mixich,  
PhD, Business Development Manager

**Corporate Partners:** The company is developing new supply chains for six key ingredients through contract cell development projects with leading Japanese pharmaceutical and chemical companies, with additional partnerships and target molecules under discussion.

**Funds Raised:** \$19.5M with \$1.4M Seed, \$18.1M in grants and additional \$0.6M in revenues.

## **Glucotrack Inc** (NASDAQ:GCTK)

**Categorical Listings:** Diagnostics, Endocrine/Metabolic, Neuropathy/Pain

**Location:** Rutherford,  
New Jersey United States

**Corporate Partners:** Cirtec Medical, The  
Technology Partnership (TTP)

**Established:** 2021

**Funds Raised:** \$65M on previous incarnation of company,  
\$25M since 2023.

**Website:** glucotrack.com

**Presenter:** Paul Goode, PhD, CEO

---

## **KisoJi Biotechnology Inc.**

**Categorical Listings:** Antibodies, Artificial Intelligence (AI), Big Data

**Location:** Montreal,  
Quebec Canada

**Corporate Partners:** Pharma and biotech (undisclosed)

**Established:** 2016

**Funds Raised:** INP

**Website:** kisojibiotech.com

**Presenter:** Gordon Ngan, MBA,  
VP, Business Development

---

## **MEDiC Life Sciences**

**Categorical Listings:** Drug Discovery, Functional Genomics, Oncology

**Location:** Mountain View,  
California United States

**Corporate Partners:** Collaborations include Bristol Myers  
Squibb for novel target discovery, Hanmi and others for  
synthetic lethal biomarkers, and Pharos iBio for drug co-  
development.

**Established:** 2020

**Website:** mediclcs.com

**Funds Raised:** \$12M in investor funding and \$5M revenue  
from pharma collaborations since 2020.

**Presenter:** Kyuho Han, PhD, CEO



## Mediwhale

**Categorical Listings:** Artificial Intelligence (AI), Cardiovascular, Diagnostics

**Location:** Seoul,  
South Korea

**Established:** 2016

**Website:** mediwhale.com

**Presenter:** Nina Shin, MBA, COO

**Corporate Partners:** Research Partners: Singapore Eye Research Institute, Yonsei Severance Hospital, University of Washington, Mayo Clinic, and HeartX in Arkansas.

**Funds Raised:** \$22M to date, including \$12M Series A2 in Sep 2024 and \$9M Series A1 in Mar 2023.

## Mesh Bio Pte Ltd

**Categorical Listings:** Bioinformatics, Cardiovascular, Endocrine/Metabolic

**Location:** Singapore

**Established:** 2018

**Website:** meshbio.com

**Presenter:** Andrew Wu, PhD,  
Co-Founder & CEO

**Corporate Partners:** Novo Nordisk, AstraZeneca

**Funds Raised:** \$4.5M Series A 2024, \$1.8M Seed in 2021.

## Molecular You

**Categorical Listings:** Bioinformatics, Longevity/Healthspan/Diseases of Aging, Personalized Medicine

**Location:** Vancouver,  
Washington United States

**Established:** 2014

**Website:** molecularyou.com

**Presenter:** Jim Kean, MBA, CEO

**Corporate Partners:** The company's lab processing operations are run primarily by HealthQuest Esoterics, California.

**Funds Raised:** \$17.25M in equity and convertible instruments, \$5M non-dilutive grants.

### Neumous Inc.

**Categorical Listings:** CNS/Neurological, Drug Delivery, Platform Technology

**Location:** Seongnam-si,  
South Korea

**Established:** 2022

**Website:** neumous.com

**Presenter:** Seohyeon Park,  
Research Manager

**Corporate Partners:** Severance Hospital and Seoul National University Bundang Hospital.

**Funds Raised:** \$1.2 M funded. A Series funding (\$4M) will be closed in Jan. 2025.

### Omniscope Limited

**Categorical Listings:** Artificial Intelligence (AI), Immunology, Platform Technology

**Location:** Dover,  
Delaware United States

**Established:** 2021

**Website:** omniscope.ai

**Presenter:** Vijay Vaswani,  
MBA, Co-Founder & CEO

**Corporate Partners:** Partner to €7M Horizon EPIVINF project, funded by the European Union, which aims to gain an understanding of how viral infections (HIV/COVID) alter epigenetic regulation of host factors.

**Funds Raised:** €5.2M Non-dilutive funding from Spain, Malta, Australia and the European Commission. €4.6M SAFE Note: Friends & Family and FoundersX Ventures.

### Pattern Computer

**Categorical Listings:** Artificial Intelligence (AI), Diagnostics, Drug Discovery

**Location:** Friday Harbor,  
Washington United States

**Established:** 2015

**Website:** patterncomputer.com

**Presenter:** Mark Anderson,  
MS, Chair & CEO

**Corporate Partners:** Current partnerships are with national labs, Fred Hutch Cancer Center, Medical College of Wisconsin and MultiCare Systems.

**Funds Raised:** Approximately \$39M. Currently in Series B, \$15M raised, \$25M left.

## PredxBio, Inc.

**Categorical Listings:** Artificial Intelligence (AI), Machine Learning, Research Tools

**Location:** Pittsburgh,  
Pennsylvania United States

**Corporate Partners:** MD Anderson Cancer Center, UPMC

**Funds Raised:** \$1.5M (includes \$7M non-dilutive).

**Established:** 2018

**Website:** predxbio.com

**Presenter:** Dusty Majumdar, PhD, CEO

---

## Qritive Pte. Ltd.

**Categorical Listings:** Artificial Intelligence (AI), Diagnostics, Research Tools

**Location:** Singapore

**Corporate Partners:** The company has partnerships with Roche Diagnostics, Motic, Sectra, Corista.

**Established:** 2017

**Funds Raised:** \$9.2M

**Website:** qritive.com

**Presenter:** Bruno Occhipinti,  
MBA, CEO

---

## Rejuve Biotech, Inc

**Categorical Listings:** Artificial Intelligence (AI), Big Data, Longevity/Healthspan/Diseases of Aging

**Location:** Orange,  
California United States

**Corporate Partners:** The company's AI is being developed with its partners at SingularityNET and TrueAGI, as well as the Artificial Superintelligence Alliance.

**Established:** 2022

**Funds Raised:** \$300K through a RegCF on Netcapital, as well as \$1M in non-dilutive funding from ecosystem and incubator, SingularityNET.

**Website:** rejuve.bio

**Presenter:** Kennedy Schaal, CEO

## SONIRE Therapeutics Inc.

**Categorical Listings:** Oncology, Oncology Combination Therapy, Robotics

**Location:** Tokyo,  
Japan

**Established:** 2020

**Website:** sonire-therapeutics.com/en

**Presenter:** Tohru Satoh,  
President, CEO & Founder

**Corporate Partners:** Hirata Corporation, which is listed on the Tokyo Stock Exchange Prime, assembles the company's devices.

**Funds Raised:** \$30M with \$4M in 2021, \$17M in 2022 and \$9M in Grants since 2021.

## SterlingBio Corp

**Categorical Listings:** Artificial Intelligence (AI), Natural Language Processing (NLP)/Large Language Models (LLM), Platform Technology

**Location:** Reno,  
Nevada United States

**Established:** 2001

**Website:** sterlingbio.com

**Presenter:** Catherine Schmidt,  
MBA, CEO

**Corporate Partners:** Non-profit collaboration with Stanford University in the areas of AI NLP technologies and clinical knowledge graph ontologies.

**Funds Raised:** SterlingBio has multiple customers and has received Seed funding. The company is seeking a Series A in Q1 2025.

## Weave Bio

**Categorical Listings:** Artificial Intelligence (AI), Drug Delivery, Platform Technology

**Location:** Claymont,  
Delaware United States

**Established:** 2023

**Website:** weave.bio

**Presenter:** Brandon Rice, MS,  
Chief Product Officer

**Corporate Partners:** INP

**Funds Raised:** Seed funding of \$10M in December 2023 with company launch in January 2024.

2025

# TECHBIO SHOWCASE



Categorical Listings



**Antibodies**

Exogene Limited

---

KisoJi Biotechnology Inc.

---

**Artificial Intelligence (AI)**

AI Proteins

---

Aikium Inc.

---

Atombeat, a DP Technology  
Company

---

Exogene Limited

---

KisoJi Biotechnology Inc.

---

Mediwhale

---

Omniscope Limited

---

Pattern Computer

---

PredxBio, Inc.

---

Qritive Pte. Ltd.

---

Rejuve Biotech, Inc

---

SterlingBio Corp

---

Weave Bio

**Autoimmune**

Avectas

---

**Big Data**

KisoJi Biotechnology Inc.

---

Rejuve Biotech, Inc

---

**Bioinformatics**

BrainScope

---

Mesh Bio Pte Ltd

---

Molecular You

---

**Biomanufacturing**

CellFE Inc.

---

Enquyst Technologies Inc

---

Fermelanta, Inc.

---

**Cardiovascular**

Mediwhale

---

Mesh Bio Pte Ltd

---

**Cell Therapy**

Adva Biotechnology Ltd

---

Avectas

---

CellFE Inc.

---

**CNS/Neurological**

BrainScope

---

Neumous Inc.

---

**CRISPR**

BrilliantStrings Therapeutics

---

**Diagnostics**

Glucotrack Inc

---

Mediwhale

---

Pattern Computer

---

Qritive Pte. Ltd.

---

**Drug Delivery**

Neumous Inc.

---

Weave Bio

---

**Drug Discovery**

Atombeat, a DP Technology  
Company

---

BrainScope

---

MEDiC Life Sciences

---

Pattern Computer

---

**Endocrine/Metabolic**

Glucotrack Inc

---

Mesh Bio Pte Ltd

---

**Functional Genomics**

MEDiC Life Sciences

---

**Gene Therapy**

Adva Biotechnology Ltd

---

Avecris Pte. Ltd.

---

**Generics**

Fermelanta, Inc.

---

**Immunology**

Omniscope Limited

---

**Immuno-oncology**

Avectas

---

CellFE Inc.

---

Exogene Limited

---

**Longevity/Healthspan/  
Diseases of Aging**

Molecular You

---

Rejuve Biotech, Inc

---

**Machine Learning**

PredxBio, Inc.

---

**Musculoskeletal**

BrilliantStrings Therapeutics

---

**Natural language  
processing (NLP)/Large  
Language Models (LLM)**

SterlingBio Corp

---



**Neuropathy/Pain**

Glucotrack Inc

---

**Oncology**

Aikium Inc.

---

MEDiC Life Sciences

---

SONIRE Therapeutics Inc.

---

**Oncology Combination  
Therapy**

SONIRE Therapeutics Inc.

---

**Personalized Medicine**

Molecular You

---

**Platform Technology**

AI Proteins

---

Aikium Inc.

---

Atombeat, a DP Technology  
Company

---

Avecris Pte. Ltd.

---

Enquyst Technologies Inc

---

Fermelanta, Inc.

---

Neumous Inc.

---

Omniscope Limited

---

SterlingBio Corp

---

Weave Bio

---

**Radiopharmaceuticals**

AI Proteins

---

**Regenerative Medicine**

Adva Biotechnology Ltd

---

BrilliantStrings Therapeutics

---

**Research Tools**

Enquyst Technologies Inc

---

PredxBio, Inc.

---

Qritive Pte. Ltd.

---

**Robotics**

SONIRE Therapeutics Inc.

---



2025

# SEED SHOWCASE

Presenting Company  
Profiles



## Aloe Therapeutics, Inc

**Categorical Listings:** Immuno-oncology, Oncology, Platform Technology

**Location:** Germantown,  
Maryland United States

**Corporate Partners:** IP is founder generated and assigned to Aloe Therapeutics.

**Established:** 2020

**Funds Raised:** \$300K: \$235K + \$65K founder funded

**Website:** aloetherapeutics.org

**Presenter:** Martha Sklavos,  
PhD, Founder & CEO

---

## Amaro Therapeutics, Inc.

**Categorical Listings:** Longevity/Healthspan/Diseases of Aging, Natural Language Processing (NLP)/Large Language Models (LLM), Platform Technology

**Location:** New York,  
New York United States

**Corporate Partners:** None

**Established:** 2021

**Funds Raised:** ~\$200K to date from 'friends and family' but the company has had considerable preclinical work conducted on its behalf.

**Website:** amarotx.com

**Presenter:** Michael French, MS, CEO

---

## Aspiro Therapeutics, Inc.

**Categorical Listings:** Pulmonary

**Location:** Tucson,  
Arizona United States

**Corporate Partners:** None

**Established:** 2024

**Funds Raised:** Currently raising an Angel round and applied for non-dilutive grants with expected funding in early 2025, followed by Seed financing.

**Website:** aspirotx.com

**Presenter:** James Lovgren,  
MBA, CEO & Co-Founder

## Bioarchitech

**Categorical Listings:** Antibodies, Oncology, Vaccines

**Location:** Oxford,  
United Kingdom

**Corporate Partners:** None

**Established:** 2022

**Funds Raised:** INP

**Website:** bioarchitech.com

**Presenter:** Kevin Maskell,  
CEO & CSO

---

## Biorevert Inc.

**Categorical Listings:** Drug Discovery, Oncology, Platform Technology

**Location:** Daejeon,  
South Korea

**Corporate Partners:** The company's oncology pipelines are currently in development with Oscotec Inc. It is also planning to do collaborative research with global pharmaceutical companies by using its MOByDiCK platform.

**Established:** 2022

**Website:** biorevert.com

**Presenter:** Sea Choi, PhD,  
Co-Founder & Chief Global Strategist

**Funds Raised:** INP

---

## BioSuperior Technology, Inc.

**Categorical Listings:** Drug Delivery, Platform Technology, Pulmonary

**Location:** Los Altos,  
California United States

**Corporate Partners:** A number of biotech companies have expressed interest in collaborating with BioSuperior.

**Established:** 2024

**Funds Raised:** \$606K in grant funding (NSF and March of Dimes) and \$250K from internal sources.

**Website:** bio-superior.com

**Presenter:** Russ Lehrman, PhD, CEO

## CereCura Nanotherapeutics Inc.

**Categorical Listings:** CNS/Neurological, Gene Therapy, Platform Technology

**Location:** Vancouver,  
British Columbia Canada

**Established:** 2022

**Website:** cerecura.com

**Presenter:** Louis-Philippe Bernier,  
PhD, CEO

**Corporate Partners:** The company is partnering with technology developers for lipids and RNA modifications.

**Funds Raised:** \$600K in pre-Seed raise, \$1.1M in non-dilutive grants.

---

## Chariot Biosciences, Inc.

**Categorical Listings:** Cell Therapy, Gene Therapy, Orphan/Rare Disease

**Location:** Baltimore,  
Maryland United States

**Established:** 2024

**Website:** chariot-bio.com

**Presenter:** Gregory (Greg) Merrill,  
Executive Director

**Corporate Partners:** LifeBridge/Sinai Hospital of Baltimore, and Science Inc.

**Funds Raised:** \$2M in grants to date and under \$1M in equity.

---

## Diadem Biotherapeutics

**Categorical Listings:** Immunology, Immuno-oncology, Platform Technology

**Location:** Torrance,  
California United States

**Established:** 2020

**Website:** diadembio.com

**Presenter:** Kuldeep Neote, PhD, CEO

**Corporate Partners:** The company is seeking biopharma partnerships.

**Funds Raised:** \$2M

## Endure Biotherapeutics, Inc.

**Categorical Listings:** Endocrine/Metabolic, Gastrointestinal, Microbiome

**Location:** Encinitas,  
California United States

**Established:** 2021

**Website:** endurebio.com

**Presenter:** Mark Suman Wilson,  
MBA, CEO

**Corporate Partners:** The company does not have a corporate partner, but has been partially sponsored by BioMarin in its early development.

**Funds Raised:** INP

---

## Epiliquid Holding, Inc

**Categorical Listings:** Epigenetics, Oncology, Platform Technology

**Location:** Wilmington,  
Delaware United States

**Established:** 2022

**Website:** epiliquid.com

**Presenter:** Alejandro Ledesma,  
MBA, CEO

**Corporate Partners:** The company has FUESMEN as a partner for its Early Access Program to test its technology and Auna Salud as a strategic partner co-developing its first lung cancer detection product.

**Funds Raised:** Approx. \$1.3M to date, through a combination of dilutive and non-dilutive funding.

---

## Esphera SynBio Inc

**Categorical Listings:** Drug Delivery, Immuno-oncology, Vaccines

**Location:** Ottawa,  
Ontario Canada

**Established:** 2023

**Website:** esphasynbio.ca

**Presenter:** Brian Lichty, PhD, CEO

**Corporate Partners:** A non-oncology application of the company's technology is being explored in collaboration with Sanofi.

**Funds Raised:** INP

## Exolvo Biosciences

**Categorical Listings:** Drug Delivery, Immunology, Oncology

**Location:** Westfield,  
New Jersey United States

**Established:** 2024

**Website:** exolvobio.com

**Presenter:** Brian Longstreet,  
CEO & Co-Founder

**Corporate Partners:** The company is currently talking with a number of Pharma companies on potential collaborations capitalizing on previous Verily relationships and its own vast industry networks.

**Funds Raised:** The company has raised a pre-Seed round and has a very favorable licensing agreement with Verily/Google Life Sciences.

## Eyegenex, Inc

**Categorical Listings:** Cell Therapy, Gene Therapy, Ophthalmic

**Location:** San Diego,  
California United States

**Established:** 2023

**Website:** eyegenex.com

**Presenter:** Prasad Sunkara,  
PhD, President & CEO

**Corporate Partners:** None yet.

**Funds Raised:** \$740K in a pre-Seed round.

## FluoSphera SA

**Categorical Listings:** Drug Discovery, Platform Technology, Research Tools

**Location:** Plan-les-Ouates,  
Switzerland

**Established:** 2021

**Website:** fluosphera.com

**Presenter:** Clelia Bourgoint,  
PhD, CEO

**Corporate Partners:** Multiplexed drug selectivity assay developed in collaboration with Revvity, antibody-drug conjugate co-developed with a Swiss mid-size pharma company (confidential), systemic biomarkers identification for a Top5 big pharma company (confidential).

**Funds Raised:** Pre-Seed round of \$1.65M.



## FlyWorks America, Inc.

**Categorical Listings:** Drug Discovery, Oncology, Platform Technology

**Location:** Pittsfield,  
Massachusetts United States

**Corporate Partners:** The company has no partnerships at the current time.

**Established:** 2024

**Funds Raised:** \$40K (¥4M) in non-dilutive grants.

**Website:** flyworks.org

**Presenter:** Jorgen (Walker) Peterson,  
PhD, MS, CEO

---

## Genicity Limited

**Categorical Listings:** Cell Therapy, Immuno-oncology, Oncology

**Location:** Galway,  
Ireland

**Corporate Partners:** None

**Established:** 2021

**Funds Raised:** €909K as of 01/2024 under SAFE from Angel investors and Enterprise Ireland.

**Website:** genicity.bio

**Presenter:** Rainer Henning, CEO

---

## Imbiome Inc.

**Categorical Listings:** Drug Delivery, Microbiome, Platform Technology

**Location:** Albany,  
New York United States

**Corporate Partners:** In discussions with several potential partners.

**Established:** 2023

**Funds Raised:** \$1M (pre-Seed) in the last eight weeks (raising \$1.5M-\$2M in total). Will be raising \$10M in H1 2025.

**Website:** imbiome.com

**Presenter:** Igor Kouzin, MEd, MBA,  
Co-Founder & Executive Chairman

## **InnoPath Therapeutics**

**Categorical Listings:** Dermatology, Oncology

**Location:** Sherman Oaks,  
California United States

**Corporate Partners:** None at this time

**Funds Raised:** ~\$500K to date.

**Established:** 2024

**Website:** [innopathtx.com](http://innopathtx.com)

**Presenter:** Peter Trepp, MBA, CEO

---

## **IowaIBO, Inc.**

**Categorical Listings:** Contract Drug Development, Oncology, Women's Health

**Location:** Fairfield,  
Iowa United States

**Corporate Partners:** INP

**Funds Raised:** Self-funded to-date.

**Established:** 2017

**Website:** [iowaiibo.com](http://iowaiibo.com)

**Presenter:** Tom McCorkle, PhD, CEO

---

## **Keylika Inc**

**Categorical Listings:** Drug Delivery, Hematology, Neurology

**Location:** Walnut Creek,  
California United States

**Corporate Partners:** The company has recently closed a pilot deal with a biopharma major to advance its hematology asset through preclinical studies.

**Established:** 2022

**Funds Raised:** INP

**Website:** [keylika.com](http://keylika.com)

**Presenter:** Buddha Chaudhuri,  
PhD, CEO & Co-Founder

## kez.biosolutions GmbH

**Categorical Listings:** Drug Discovery, Platform Technology

**Location:** Potsdam,  
Germany

**Corporate Partners:** Pre-revenue

**Funds Raised:** €1.2M in pre-Seed plus €350K in grants.

**Established:** 2022

**Website:** kez.bio

**Presenter:** Jan Degen,  
Managing Director & COO

---

## Lime Therapeutics

**Categorical Listings:** Drug Discovery, Oncology, Oncology Combination Therapy

**Location:** New York,  
New York United States

**Corporate Partners:** The company is actively seeking corporate partners for its platform discovery efforts and therapeutic pipeline.

**Established:** 2022

**Funds Raised:** INP

**Website:** limetherapeutics.com

**Presenter:** Shardule Shah,  
PhD, MBA, CEO

---

## Magsorbeo Biomedical

**Categorical Listings:** Other, Platform Technology

**Location:** Detroit,  
Michigan United States

**Corporate Partners:** Product launch, regulatory, and clinical strategy being drafted with support from Zimmer Biomet through Plug and Play Ventures Medtech Accelerator.

**Established:** 2022

**Funds Raised:** \$1M in Pre-Seed funds with additional non-dilutive support.

**Website:** magsorbeo.com

**Presenter:** Jake Edick,  
MBA, CEO & Co-Founder

## Myostellar

**Categorical Listings:** Drug Discovery, Musculoskeletal, Regenerative Medicine

**Location:** Clayton,  
Australia

**Corporate Partners:** Exploring potential partnerships.

**Established:** 2022

**Funds Raised:** \$2M

**Website:** [monash.edu/monash-innovation/impact/spinouts/myostellar](https://monash.edu/monash-innovation/impact/spinouts/myostellar)

**Presenter:** Aoife Cullen,  
PhD, Head, Commercialization

## Myria Biosciences AG

**Categorical Listings:** Artificial Intelligence (AI), Drug Discovery, Platform Technology

**Location:** Basel,  
Switzerland

**Corporate Partners:** In a partnership with a Top10 Pharma company for an undisclosed indication.

**Established:** 2022

**Funds Raised:** INP

**Website:** [myria.bio](https://myria.bio)

**Presenter:** Irene Wuethrich, MS, COO

## Nabugen Therapeutics

**Categorical Listings:** Artificial Intelligence (AI), CNS/Neurological, Psychiatric

**Location:** Holden,  
Massachusetts United States

**Corporate Partners:** INP

**Established:** 2024

**Funds Raised:** INP

**Website:** [nabugen.bio](https://nabugen.bio)

**Presenter:** Priyal Sheth,  
MS, CBO & Co-Founder

## NeuraViva Therapeutics, Inc.

**Categorical Listings:** Artificial Intelligence (AI), Mitochondrial Therapeutic, Oncology

**Location:** Burlingame,  
California United States

**Corporate Partners:** NeuraViva's assets are not currently  
partnered.

**Established:** 2024

**Funds Raised:** NeuraViva is in the pre-Seed stage of  
funding.

**Website:** neuraviva.com

**Presenter:** Douglas A Hamilton, MBA,  
President & CEO

---

## Neurenati Therapeutics Inc

**Categorical Listings:** Inflammation, Orphan/Rare Disease, Regenerative Medicine

**Location:** Montreal,  
Quebec Canada

**Corporate Partners:** None at this point.

**Established:** 2023

**Funds Raised:** \$2M from Angel investors and Invest Quebec  
(Impulsion PME program).

**Website:** neurenati.com

**Presenter:** Maxime Ranger,  
PhD, MBA, CEO

---

## NKILT Therapeutics, Inc.

**Categorical Listings:** Cell Therapy, Immuno-oncology, Oncology

**Location:** Houston,  
Texas United States

**Corporate Partners:** INP

**Established:** 2021

**Funds Raised:** \$1.5M

**Website:** nkilt.com

**Presenter:** Raphaël (Rapha) G.Ognar,  
MSc, MBA, President & CEO,  
Co-Founder

## NUP-CTx Inc.

**Categorical Listings:** Drug Delivery, Oncology, Platform Technology

**Location:** Cape Coral,  
Florida United States

**Corporate Partners:** Universities.

**Established:** 2024

**Funds Raised:** INP

**Website:** nupctx.com

**Presenter:** Kai Blau,  
PhD, Business Director

---

## Olfera

**Categorical Listings:** CNS/Neurological, Drug Delivery, Drug Discovery

**Location:** San Francisco,  
California United States

**Corporate Partners:** The company is in partnership  
discussions with a few Pharma companies.

**Established:** 2022

**Funds Raised:** \$550K in a pre-Seed round.

**Website:** olferatx.com

**Presenter:** Parnian Lak,  
PharmD, PhD, CEO

---

## Omios Biologics

**Categorical Listings:** Gene Therapy, Immuno-oncology, Oncology Combination Therapy

**Location:** Oakland,  
California United States

**Corporate Partners:** OV program is developed in  
collaboration with scientists and clinicians at NYU, ASU,  
Mayo Clinic and Moffitt Cancer Center. Transgene program  
is developed with Twist Bioscience and ValiRx.

**Established:** 2023

**Website:** [linkedin.com/company/omios-biologics/](https://www.linkedin.com/company/omios-biologics/)

**Funds Raised:** INP

**Presenter:** Aldo Pourchet,  
PhD, DVM, Founder & CEO

## OncoRx Insights, Inc.

**Categorical Listings:** Machine Learning, Oncology, Personalized Medicine

**Location:** Boulder,  
Colorado United States

**Corporate Partners:** City of Hope, Private Health  
Management

**Established:** 2022

**Funds Raised:** Company is funded by founders; seeking  
Seed investment of \$4M.

**Website:** oncorxinsights.com

**Presenter:** Dave Parkhill,  
CEO & Co-Founder

## Plurify

**Categorical Listings:** Bioinformatics, Biomanufacturing, Cell Therapy

**Location:** Cambridge,  
United Kingdom

**Corporate Partners:** None yet. Many in the funnel.

**Established:** 2023

**Funds Raised:** ~£850K = ~\$1.1M

**Website:** plurify.bio

**Presenter:** Djordje Djordjevic,  
PhD, CEO & Co-Founder

## PNAS Therapeutics Ltd

**Categorical Listings:** Drug Delivery, Platform Technology

**Location:** London,  
United Kingdom

**Corporate Partners:** PNAS is conducting research in  
collaboration with Seoul National University Hospital  
and Mitolmmune Therapeutics Inc. and is establishing a  
business partnership based on the networks of Oxford  
University and BIA.

**Established:** 2024

**Website:** pnastx.com

**Presenter:** Hyunwoo Shin, PhD, CEO

**Funds Raised:** In 2024, the company secured \$0.2M in  
investment and received a non-diluted \$1.2M grant.

## Ponce AI, Inc.

**Categorical Listings:** Artificial Intelligence (AI), Diagnostics, Longevity/Healthspan/Diseases of Aging

**Location:** San Francisco,  
California United States

**Established:** 2023

**Website:** ponce.ai

**Presenter:** Sugam Arora, MBA, CEO

**Corporate Partners:** The company is working exclusively with board-certified MDs as design partners across dermatology and plastic surgery such as: Judge MD (plastic surgery), Maan Plastic Surgery, and Kaveri Karhade (dermatology).

**Funds Raised:** \$350K in early 2024 in friends & family/Angel round.

## Praana, Inc.

**Categorical Listings:** Diagnostics, Neurology, Oncology

**Location:** Chicago,  
Illinois United States

**Established:** 2022

**Website:** praanatech.com

**Presenter:** Mythra Varun Nemallapudi,  
PhD, MS, Chairman

**Corporate Partners:** NVIDIA, Taiwan Applied Crystals, Alzheimer's Association

**Funds Raised:** \$800K in Angel investment until 2024, \$1.5M in grants, \$3M milestone in June 2025.

## Primagene Therapeutics, Inc.

**Categorical Listings:** Cell Therapy, Immunology, Renal

**Location:** Houston,  
Texas United States

**Established:** 2024

**Website:** primagenetx.com

**Presenter:** Michael (Mike) Beauregard,  
CEO & Co-Founder

**Corporate Partners:** None

**Funds Raised:** The company has applied to non-dilutive funding sources, otherwise none.



## QuanMol Tech, Inc.

**Categorical Listings:** Artificial Intelligence (AI), Oncology, Platform Technology

**Location:** San Carlos,  
California United States

**Established:** 2022

**Website:** quanmol.com

**Presenter:** Bo Li, PhD,  
CSO & Co-Founder

**Corporate Partners:** Createrna, Avstera, BridGene and many others.

**Funds Raised:** \$2M in 2022, and despite being self sufficient, the company is planning to raise more to expand.

## Radiance Biopharma

**Categorical Listings:** Antibodies, Oncology

**Location:** Boston,  
Massachusetts United States

**Established:** 2023

**Website:** radiancebiopharma.com

**Presenter:** Robert K. Brooks, CEO

**Corporate Partners:** Negotiating

**Funds Raised:** \$1M

## Robles BioCeutics

**Categorical Listings:** Dermatology, Fibrosis, Regenerative Medicine

**Location:** San Diego,  
California United States

**Established:** 2024

**Website:** roblesbioceutics.com

**Presenter:** Maria Robles, CEO

**Corporate Partners:** The company partners with BioCenrium LLC for basic research.

**Funds Raised:** \$1M

## Sentinel Biotherapeutics

**Categorical Listings:** Immuno-oncology, Oncology Combination Therapy, Platform Technology

**Location:** Houston,  
Texas United States

**Established:** 2023

**Website:** sentinelbiotx.com

**Presenter:** Rima Chakrabarti,  
MD, CEO

**Corporate Partners:** Immuno-oncology pipeline is being developed with clinical partners at MD Anderson Cancer Center and Baylor College of Medicine. Additional support is received from RBL, LLC, a venture creation studio.

**Funds Raised:** Just over \$100K from the founding team.

---

## SeraGene Therapeutics

**Categorical Listings:** Gene Therapy, Hematology, Orphan/Rare Disease

**Location:** Vancouver,  
British Columbia Canada

**Established:** 2022

**Website:** seragenetx.com

**Presenter:** Erika Siren, PhD, CEO

**Corporate Partners:** The company's thrombosis pipeline asset (SG-002) is currently being funded by the U.S. Department of Defense.

**Funds Raised:** \$520K in pre-Seed funding with an additional \$820K in grants to develop secondary asset.

---

## Signal Bioscience

**Categorical Listings:** Diagnostics, Drug Discovery, Research Tools

**Location:** Ann Arbor,  
Michigan United States

**Established:** 2023

**Website:** signalbioscience.com

**Presenter:** John Cunningham,  
MS, MBA, CEO

**Corporate Partners:** None to date

**Funds Raised:** \$500K at founding in Q2 2023.

## Sireau Labs

**Categorical Listings:** Orphan/Rare Disease, Platform Technology

**Location:** Cambridge,  
United Kingdom

**Corporate Partners:** INP

**Established:** 2022

**Funds Raised:** \$250K from private sources.

**Website:** sireau.com

**Presenter:** Nick Sireau,  
PhD, MSc, Co-Founder & Director

---

## SiVEC Biotechnologies, Inc.

**Categorical Listings:** Drug Delivery, Gene Therapy, Oncology

**Location:** Fort Collins,  
Colorado United States

**Corporate Partners:** No corporate partners; prior collaboration with gene editing company evaluating the BactPac delivery platform. Attracting big pharma like Novartis, Bayer, Genentech, etc, interested in KRAS oncology program.

**Established:** 2022

**Website:** sivecbiotechnologies.com

**Funds Raised:** INP

**Presenter:** Lyndsey Linke,  
PhD, ME, CEO

---

## Stimuliver ApS

**Categorical Listings:** Cell Therapy, Hepatic, Regenerative Medicine

**Location:** Copenhagen,  
Denmark

**Corporate Partners:** Technology has been validated by several undisclosed corporate partners.

**Established:** 2022

**Funds Raised:** Approximately €2M in convertible loans and grants.

**Website:** stimuliver.bio

**Presenter:** Giles Dudley, PhD, CBO

## Stratum Bioscience

**Categorical Listings:** Artificial Intelligence (AI), Dermatology, Platform Technology

**Location:** New York,  
New York United States

**Established:** 2023

**Website:** stratumbio.com

**Presenter:** Ross Lane Pearlman,  
MD, CEO

**Corporate Partners:** Stratum Bioscience is a resident company of JLABS@NYC, Johnson and Johnson's Life Sciences incubator.

**Funds Raised:** INP

---

## Ternalys Therapeutics, Inc.

**Categorical Listings:** CNS/Neurological, Epigenetics, Oncology

**Location:** Chapel Hill,  
North Carolina United States

**Established:** 2022

**Website:** ternalys.com

**Presenter:** Kenneth Moch, MBA,  
Chairman & CEO, Co-Founder

**Corporate Partners:** INP

**Funds Raised:** Initial work funded at Mass General Brigham. In 2023, Ternalys received a \$275K STTR from NCI to progress this technology.

---

## TippingPoint Biosciences

**Categorical Listings:** Drug Discovery, Epigenetics, Platform Technology

**Location:** San Francisco,  
California United States

**Established:** 2022

**Website:** tippingpointbiosciences.com

**Presenter:** Laura Hsieh,  
PhD, CEO & Founder

**Corporate Partners:** The company is in early conversations with pharma companies but has no partnership deals yet.

**Funds Raised:** \$1.7M in pre-Seed funding.

## TMAB Therapeutics, Inc

**Categorical Listings:** Antibodies, Immuno-oncology, Oncology

**Location:** Houston,  
Texas United States

**Corporate Partners:** Participated in the Texas Medical Center Accelerator for Cancer Therapeutics.

**Established:** 2023

**Funds Raised:** \$1.5M

**Website:** tmabtherapeutics.com

**Presenter:** Tinashe Chandauka,  
PhD, CEO

---

## Trio Vance Development Co

**Categorical Listings:** Cell Therapy, Gene Therapy, Regenerative Medicine

**Location:** Vista,  
California United States

**Corporate Partners:** The company doesn't have any corporate partners yet.

**Established:** 2023

**Funds Raised:** \$2M

**Website:** trio Vance.com

**Presenter:** Blanca Segura, PhD, CEO

---

## Tundra Targeted Therapeutics, Inc.

**Categorical Listings:** Antibodies, Cell Therapy, Immuno-oncology

**Location:** Milwaukee,  
Wisconsin United States

**Corporate Partners:** Open to partnering discussions.

**Established:** 2022

**Funds Raised:** \$1.5M to date.

**Website:** INP

**Presenter:** Jediah White,  
MBA, President

## U-Ploid Biotechnologies

**Categorical Listings:** Drug Delivery, Longevity/Healthspan/Diseases of Aging, Women's Health

**Location:** Oxford,  
United Kingdom

**Corporate Partners:** Clinical partners in U.S., Canada and UK. Currently no corporate pharma development partners.

**Established:** 2024

**Funds Raised:** Pre-Seed in Summer of 2024.

**Website:** u-ploid.com

**Presenter:** Jordan Abdi,  
MD, Co-Founder & CEO

---

## Veirulence Ltd

**Categorical Listings:** Drug Discovery, Infectious Disease, Pulmonary

**Location:** London,  
United Kingdom

**Corporate Partners:** Recent informal discussion with Shionogi.

**Established:** 2022

**Funds Raised:** Less than \$1M.

**Website:** veirulence.com

**Presenter:** Rory Triniman, PhD, CEO

---

## Xella Health, PBC

**Categorical Listings:** Diagnostics, Platform Technology, Women's Health

**Location:** Redwood City,  
California United States

**Corporate Partners:** The company has clinical study partnerships with several well-known fertility and women's health practices.

**Established:** 2023

**Funds Raised:** INP

**Website:** joinxella.com

**Presenter:** Kelly Jacob,  
MBA, MSE, CEO

## **YouthBio Therapeutics**

**Categorical Listings:** CNS/Neurological, Gene Therapy, Longevity/Healthspan/Diseases of Aging

**Location:** Lewes,  
Delaware United States

**Corporate Partners:** Product is being developed in  
partnership with CROs abroad.

**Established:** 2021

**Funds Raised:** INP

**Website:** [youthbiotx.com](http://youthbiotx.com)

**Presenter:** Yuri Deigin, MBA, CEO

---

---

The image features a dark, atmospheric background with a large, glowing sphere resembling a planet or moon. In the foreground, several small green seedlings are planted in stacks of coins, arranged in a line that recedes into the distance. The overall theme is growth, investment, and future potential.

2025

# SEED SHOWCASE

Categorical Listings





## **Antibodies**

Bioarchitech

---

Radiance Biopharma

---

TMAB Therapeutics, Inc

---

Tundra Targeted Therapeutics, Inc.

---

## **Artificial Intelligence (AI)**

Myria Biosciences AG

---

Nabugen Therapeutics

---

NeuraViva Therapeutics, Inc.

---

Ponce AI, Inc.

---

QuanMol Tech ,Inc.

---

Stratum Bioscience

---

## **Bioinformatics**

Plurify

---

## **Biomanufacturing**

Plurify

---

## **Cell Therapy**

Chariot Biosciences, Inc.

---

Eyegenex, Inc

---

Genicity Limited

---

NKILT Therapeutics, Inc.

---

Plurify

---

Primagene Therapeutics, Inc.

---

## **Cell Therapy (Cont'd)**

Stimuliver ApS

---

Triovance Development Co

---

Tundra Targeted Therapeutics, Inc.

---

## **CNS/Neurological**

CereCura Nanotherapeutics Inc.

---

Nabugen Therapeutics

---

Olfera

---

Ternalys Therapeutics, Inc.

---

YouthBio Therapeutics

---

## **Contract Drug Development**

lowalBO, Inc.

---

## **Dermatology**

InnoPath Therapeutics

---

Robles BioCeutics

---

Stratum Bioscience

---

## **Diagnostics**

Ponce AI, Inc.

---

Praana, Inc.

---

Signal Bioscience

---

Xella Health, PBC

---

**Drug Delivery**

BioSuperior Technology, Inc.

---

Esphera SynBio Inc

---

Exolvo Biosciences

---

Imbiome Inc.

---

Keylika Inc

---

NUP-CTx Inc.

---

Olfera

---

PNAS Therapeutics Ltd

---

SiVEC Biotechnologies, Inc.

---

U-Ploid Biotechnologies

---

**Drug Discovery**

Biorevert Inc.

---

FluoSphera SA

---

FlyWorks America, Inc.

---

kez.biosolutions GmbH

---

Lime Therapeutics

---

Myostellar

---

Myria Biosciences AG

---

Olfera

---

Signal Bioscience

---

TippingPoint Biosciences

---

Veirulence Ltd

---

**Endocrine/Metabolic**

Endure Biotherapeutics, Inc.

---

**Epigenetics**

Epiliquid Holding, Inc

---

Ternalys Therapeutics, Inc.

---

TippingPoint Biosciences

---

**Fibrosis**

Robles BioCeutics

---

**Gastrointestinal**

Endure Biotherapeutics, Inc.

---

**Gene Therapy**

CereCura Nanotherapeutics Inc.

---

Chariot Biosciences, Inc.

---

Eyegenex, Inc

---

Omios Biologics

---

SeraGene Therapeutics

---

SiVEC Biotechnologies, Inc.

---

Triovance Development Co

---

YouthBio Therapeutics

---

**Hematology**

Keylika Inc

---

SeraGene Therapeutics

---

**Hepatic**

Stimuliver ApS

---

**Immunology**

Diadem Biotherapeutics

---

Exolvo Biosciences

---

Primagene Therapeutics, Inc.

---

**Immuno-oncology**

Aloe Therapeutics, Inc

---

Diadem Biotherapeutics

---

Esphera SynBio Inc

---

Genicity Limited

---

NKILT Therapeutics, Inc.

---

Omios Biologics

---

Sentinel Biotherapeutics

---

TMAB Therapeutics, Inc

---

Tundra Targeted Therapeutics, Inc.

---

**Infectious Disease**

Veirulence Ltd

---

**Inflammation**

Neurenati Therapeutics Inc

---

**Longevity/Healthspan/  
Diseases of Aging**

Amaro Therapeutics, Inc.

---

Ponce AI, Inc.

---

U-Ploid Biotechnologies

---

YouthBio Therapeutics

---

**Machine Learning**

OncoRx Insights, Inc.

---

**Microbiome**

Endure Biotherapeutics, Inc.

---

Imbiome Inc.

---

**Mitochondrial  
Therapeutic**

NeuraViva Therapeutics, Inc.

---

**Musculoskeletal**

Myostellar

---

**Natural Language  
Processing (NLP)/Large  
Language Models (LLM)**

Amaro Therapeutics, Inc.

---

**Neurology**

Keylika Inc

---

Praana, Inc.

---

**Oncology**

Aloe Therapeutics, Inc

---

Bioarchitech

---

Biorevert Inc.

---

Epiliquid Holding, Inc

---

Exolvo Biosciences

---

FlyWorks America, Inc.

---

Genicity Limited

---

InnoPath Therapeutics

---

lowalBO, Inc.

---

Lime Therapeutics

---

NeuraViva Therapeutics, Inc.

---

NKILT Therapeutics, Inc.

---

NUP-CTx Inc.

---

OncoRx Insights, Inc.

---

Praana, Inc.

---

QuanMol Tech ,Inc.

---

Radiance Biopharma

---

SiVEC Biotechnologies, Inc.

---

Ternalys Therapeutics, Inc.

---

TMAB Therapeutics, Inc

---

**Oncology Combination  
Therapy**

Lime Therapeutics

---

Omios Biologics

---

Sentinel Biotherapeutics

---

**Ophthalmic**

Eyegenex, Inc

---

**Orphan/Rare Disease**

Chariot Biosciences, Inc.

---

Neurenati Therapeutics Inc

---

SeraGene Therapeutics

---

Sireau Labs

---

**Other**

Magsorbeo Biomedical

---

**Personalized Medicine**

OncoRx Insights, Inc.

---

**Platform Technology**

Aloe Therapeutics, Inc

---

Amaro Therapeutics, Inc.

---

Biorevert Inc.

---

BioSuperior Technology, Inc.

---

CereCura Nanotherapeutics Inc.

---

Diadem Biotherapeutics

---

**Platform Technology (Cont'd)**

Epiliquid Holding, Inc

---

FluoSphera SA

---

FlyWorks America, Inc.

---

Imbiome Inc.

---

kez.biosolutions GmbH

---

Magsorbeo Biomedical

---

Myria Biosciences AG

---

NUP-CTx Inc.

---

PNAS Therapeutics Ltd

---

QuanMol Tech ,Inc.

---

Sentinel Biotherapeutics

---

Sireau Labs

---

Stratum Bioscience

---

TippingPoint Biosciences

---

Xella Health, PBC

---

**Psychiatric**

Nabugen Therapeutics

---

**Pulmonary**

Aspiro Therapeutics, Inc.

---

BioSuperior Technology, Inc.

---

Veirulence Ltd

---

**Regenerative Medicine**

Myostellar

---

Neurenati Therapeutics Inc

---

Robles BioCeutics

---

Stimuliver ApS

---

Triovance Development Co

---

**Renal**

Primagene Therapeutics, Inc.

---

**Research Tools**

FluoSphera SA

---

Signal Bioscience

---

**Vaccines**

Bioarchitech

---

Esphera SynBio Inc

---

**Women's Health**

lowalBO, Inc.

---

U-Ploid Biotechnologies

---

Xella Health, PBC

---



Co-produced by

